{"rep-contact":[{"ID":"52709","post_title":"ADENURIC\u00ae (febuxostat)","post_content":"Access the Adenuric<sup>\u00ae<\/sup> PI <a href=\"https:\/\/www.guildlink.com.au\/gc\/ws\/fk\/pi.cfm?product=fkpadent\">here<\/a>\r\n\r\nThe recommended oral dose of ADENURIC is 40 mg or 80 mg once daily with or without food. The recommended starting dose of ADENURIC is 40 mg once daily. If serum uric acid (sUA) is greater than 357 micromole\/L (6 mg\/dL) after 2-4 weeks, ADENURIC 80 mg once daily is recommended. The 80 mg tablet can be split into two equal halves in order to provide a 40 mg dose. Prescribers should advise patients on how to break the tablets in half. Testing for the target serum uric acid level of less than 357 micromole\/L (6 mg\/dL) may be performed as early as two weeks after initiating ADENURIC therapy. Gout flare prophylaxis of up to 6 months is recommended (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Acute Gouty Attacks (gout flares)).\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Adenuric-PBS.png\"><img class=\"aligncenter size-full wp-image-52719\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Adenuric-PBS.png\" alt=\"\" width=\"1350\" height=\"124\" \/><\/a>\r\n\r\nPlease review the approved Product information before prescribing. The product information can be accessed at\u00a0<a href=\"http:\/\/www.menarini.com.au\/PI\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=http:\/\/www.menarini.com.au\/PI&amp;source=gmail&amp;ust=1664932454879000&amp;usg=AOvVaw1kqYC8khPQgMQYgHrVKhUF\">www.menarini.com.au\/PI<\/a>\r\n\r\nApproval code: ADE-AU-1907","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Screen-Shot-2023-03-01-at-4.26.23-PM.png","cat_name":"I would like a Rep to contact me","slug":"rep-contact","sku_code":null}],"further-training":[{"ID":"42837","post_title":"Novalac Allergy Premium Infant Formula Powder 800g","post_content":"<strong>NOVALAC Allergy<\/strong> has been scientifically formulated from protein sourced from rice, for babies unable to tolerate cow\u2019s milk formula or with a confirmed cow\u2019s milk protein allergy (CMPA). Novalac Allergy is also suitable for lactose intolerant babies.\r\n\r\nKey benefits of Novalac Allergy:\r\n<ul>\r\n \t<li><strong>The Australasian Society of Clinical Immunology and Allergy (ASCIA) recommends rice protein-based infant formula as a first choice for infants with CMPA when breastfeeding is not possible<sup>1*<\/sup><\/strong>\r\n<ul>\r\n \t<li><strong>Novalac Allergy is the\u00a0<u>only<\/u> rice protein based infant formula in the ASCIA guidelines that has product specific hypo-allergenicity and growth studies.<sup>1<\/sup><\/strong><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Hypoallergenic - Tolerated by &gt;90% of infants with confirmed CMPA<sup>2-4<\/sup>\r\n<ul>\r\n \t<li>Reduces allergy symptoms associated with CMPA including regurgitation, eczema, diarrhoea and constipation<sup>2-4<\/sup><\/li>\r\n \t<li>Helps babies return to normal weight &amp; growth patterns<sup>2-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Pleasant taste, unlike some extensively hydrolysed or amino-acid-based formulas<sup>2,3,7<\/sup><\/li>\r\n \t<li>Suitable to lactose-intolerant babies<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n \t<li>Contains Omega 3 (\u03b1-Linolenic acid) and 6 (Linoleic acid) from vegetable source<\/li>\r\n \t<li><strong>No prescription needed<\/strong> (Available only from pharmacy and online)<\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Allergy-Product-Information-and-Evidence.pdf\">Novalac Allergy Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/www.allergy.org.au\/hp\/papers\/guide-for-milk-substitutes-cows-milk-allergy\"><u>Australasian Society of Clinical Immunology and Allergy (ASCIA) Guide for Milk Substitutes in Cow\u2019s Milk Allergy\u00a0<\/u><\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/08\/Novalac-Allergy-NIP-AF-07488-2.pdf\">Novalac Allergy Nutritional Information Panel\u00a0<\/a><\/li>\r\n<\/ul>\r\n*Unless allergic to rice.\r\n\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Australasian Society of Clinical Immunology and Allergy (ASCIA), Guide for milk substitutes in cow\u2019s milk allergy, June 2023.<\/li>\r\n \t<li>Vandenplas Y et al. Eur J Paediatr. 2014; 173(9);1209-16<\/li>\r\n \t<li>Vandenplas Y et al. Arch Dis Child. 2014; 99:933-6<\/li>\r\n \t<li>Reche M et al. Patriatr Allergy Immunol. 2010; 21:577-85<\/li>\r\n \t<li>D\u2019Auria E et al. J Int Med Res. 2003; 31:215-22<\/li>\r\n \t<li>Agostoni C et al. Pediatr Allergy Immunol. 2007; 18:599-606<\/li>\r\n \t<li>Pedrosa M et al. J Investig Allergol Clin Immunol. 2006; 16:351-6<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-15-at-11.36.22-am.png","cat_name":"I would like to request further training on this product for me and\/or my staff by an Aspen Pharmacare representative.","slug":"further-training","sku_code":null},{"ID":"60218","post_title":"Novalac Constipation Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Constipation<\/strong> is specifically formulated to provide a balanced blend of nutrients to help soften stools, increase stool frequency, and relieve pain and discomfort.<sup>1-4<\/sup>\r\n\r\nKey benefits of Novalac Constipation:\r\n<ul>\r\n \t<li>91.6% of cases of infant constipation resolved within 7 days<sup>1<\/sup><\/li>\r\n \t<li>Helps manage constipation without the use of laxatives while giving babies essential nutrients.<sup>2-4<\/sup><\/li>\r\n \t<li>Novalac Constipation has been shown to significantly:\r\n<ul>\r\n \t<li>increase the water content of stools<sup>2<\/sup><\/li>\r\n \t<li>improve stool consistency and frequency<sup>1-4<\/sup><\/li>\r\n \t<li>reduce pain and discomfort with defecation<sup>1-3<\/sup><\/li>\r\n \t<li>reduce the need for manual assistance with defecation<sup>1,2<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Shortens intestinal transit time by increasing the osmotic load through a specially formulated combination of:\r\n<ul>\r\n \t<li>increased lactose (100% of carbohydrates) - produces an osmotic effect and may create a prebiotic effect when metabolised in the colon to help stimulate bowel movements<sup>1-3<\/sup><\/li>\r\n \t<li>increased magnesium to help increase water content<sup>1,4<\/sup><\/li>\r\n \t<li>an optimal calcium to phosphorus ratio of 2:1 which helps soften stools<sup>4-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Information-and-Evidence-NOV-08668-E0726.pdf\">Novalac Constipation Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Nutritional-Information.pdf\">Novalac Constipation Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li style=\"list-style-type: none;\">\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol 2008;14(2):248\u2013254.<\/li>\r\n \t<li>Infante DD, et al. Nut Journal. 2011;10:55.<\/li>\r\n \t<li>Le Luyer B, et al. RIP 2002; Tome XXXI;316:5\u20138. 33.<\/li>\r\n \t<li>Benninga MA, et al. Pediatr Gastroenterol Hepatol Nutr 2019;22(3):270281.<\/li>\r\n \t<li>Kesavelu D, et al. Clin Ep &amp; Glob Health 6. 2018;5\u20139.<\/li>\r\n \t<li>Khinchi M, et al. J Pediatr Gastroenterol &amp; Nutr. 1999;28(5):591.<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Constip_PackShot.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff by an Aspen Pharmacare representative.","slug":"further-training","sku_code":null},{"ID":"60224","post_title":"Novalac Reflux Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Reflux<\/strong> specialty infant formula is specifically formulated to help resolve reflux symptoms in infants, leading to a significant reduction in regurgitations, decreased time for bottle feeding, and increased volume of feeds.<sup>1<\/sup>\r\n\r\nKey benefits of Novalac Reflux:\r\n<ul>\r\n \t<li>81% of reflux case in infants resolved within 6 days<sup>1<\/sup><\/li>\r\n \t<li>Novalac Reflux has been shown to:\r\n<ul>\r\n \t<li>significantly reduce frequency and intensity of regurgitations and exposure of the oesophageal mucosa to acid.<sup>2<\/sup><\/li>\r\n \t<li>significantly increase feeding volume, gastric emptying and weight gain.<sup>3<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Thickens in the stomach, not the bottle, so it is easy for baby to drink and helps the feed stay down.<sup>1<\/sup><\/li>\r\n \t<li>Casein-dominant formula which helps prevent regurgitation and, in conjunction with specially treated cornstarch, encourages gastric emptying.<sup>1,3<\/sup><\/li>\r\n \t<li>Contains cornstarch with a high level of amylopectin for ease of digestion.<sup>2,4,5<\/sup><\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Product-Information-and-Evidence.pdf\">Novalac Reflux Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Nutritional-Information.pdf\">Novalac Reflux Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008;14(2):248\u201354.<\/li>\r\n \t<li>Xinias I, et al. Dig Liver Dis. 2005;37(1):23\u201327.<\/li>\r\n \t<li>Chao HC, et al. Dis Esophagus. 2007;20(2):155-60.<\/li>\r\n \t<li>Ketthaisong, et al. J Food Sci Technol, 2015; 52, 6529\u20136537.<\/li>\r\n \t<li>Lin A, et al. Molecules, 2017;22, 1526<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Reflux_PackShot.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff by an Aspen Pharmacare representative.","slug":"further-training","sku_code":null},{"ID":"60228","post_title":"Novalac Colic Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Colic<\/strong> has been scientifically formulated for infants with colic and associated symptoms such as gas and bloating.\r\n\r\nKey benefits of Novalac Colic:\r\n<ul>\r\n \t<li>87.6% of cases of colic in infants were shown to be resolved within 8 days<sup>1<\/sup><\/li>\r\n \t<li>Has been shown to significantly reduce gas, intestinal bloating and crying<sup>1,2<\/sup><\/li>\r\n \t<li>Contains easily digestible maltodextrin (70% of total carbohydrates) and a reduced proportion of lactose (30% of total carbohydrates) to reduce the risk of excessive gas which may be caused by the malabsorption of\u00a0lactose in the colon.<sup>2,3<\/sup><\/li>\r\n \t<li>Contains a Casein: Whey ratio of 40:60 to ease digestive discomfort to help infants to settle.<sup>4,5<\/sup><\/li>\r\n \t<li>Manages colic whilst feeding and nourishing baby with essential vitamins and minerals.<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Information-and-Evidence-NOV-08669-E0726.pdf\">Novalac Colic Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Nutritional-Information.pdf\">Novalac Colic Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\nNot suitable for general use and should be used under medical supervision.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008; 14(2):248\u201354.<\/li>\r\n \t<li>Infante DD, et al. World J Gastroenterol. 2011;17(16):2104\u20138.<\/li>\r\n \t<li>Hofman DL, et al. Crit Rev Food Sci Nutr. 2016; 56(12):2091\u2013100.<\/li>\r\n \t<li>Martin CR, et al. Nutrients. 2016; 8(5):279.<\/li>\r\n \t<li>Rafiee Tari N, et al. J Dairy Sci 2018;101(4): 2851\u201361.<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Colic_PackShot.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff by an Aspen Pharmacare representative.","slug":"further-training","sku_code":null}],"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff":[{"ID":"43716","post_title":"FERRO F TAB","post_content":"Each tablet contains Ferrous Fumerate 310mg (equivalent to elemental iron 100mg) + Folic Acid 350\u00b5g\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 2 Ferro-F-Tab tablets down to 1 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b><u><\/u>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-53-12-pm\/\"><img class=\"aligncenter size-full wp-image-43730\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.53.12-pm.png\" alt=\"\" width=\"536\" height=\"767\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-F-TAB-ANGLED.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"43715","post_title":"FERRO TAB","post_content":"<!--more-->Each tablet contains Ferrous Fumerate 200mg (equivalent to 67.5mg elemental iron) and does not include any other vitamins or minerals that can affect absorption<u>\r\n<\/u>\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 3 Ferro-Tab tablets down to 2 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-43-53-pm\/\"><img class=\"aligncenter size-full wp-image-43729\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.43.53-pm.png\" alt=\"\" width=\"504\" height=\"665\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-TAB-ANGLED.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"45376","post_title":"a2 MILK\u2122 FULL CREAM UHT","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/a2milk_hcp-booklet_mar21\/\">a2 Milk HCP Booklet<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/a2nutrition4professionals.com.au\/\">HCP website<\/a>\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45381\" rel=\"attachment wp-att-45381\"><img class=\"alignleft size-full wp-image-45381\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.21.40-pm.png\" alt=\"\" width=\"743\" height=\"1052\" \/><\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45382\" rel=\"attachment wp-att-45382\"><img class=\"alignleft size-full wp-image-45382\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.22.04-pm.png\" alt=\"\" width=\"745\" height=\"783\" \/><\/a>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/UHT-packshot.png","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"50181","post_title":"NOVATEARS\u00ae","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/31942-novatears-gpdetailer-a4-singlepage-f\/\">NovaTears Detail aid<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/mysamples.com.au\/34470-consumer-flyer-au-a5-148x210-v1\/\">Patient Flyer<\/a>\r\n\r\nView the NovaTears<sup>\u00ae<\/sup> Product Information video below.\r\n\r\n<iframe title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/tpYqOwZBI24\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nNovaTears\u00ae is a patented preservative-free eye lubricant, which acts as a lipid layer substitute and evaporative barrier for improved tear film stability and quality.\r\n\r\nPreservative, Phosphate &amp; Aqueous Free. Spreads quickly &amp; easily on the eye\r\n\r\nPleasant, warm silky feeling with no stinging or blurring\r\n\r\nClinically validated with significant improvements in signs &amp; symptoms for patients with Evaporative Dry Eye Disease &amp; Meibomian Gland Dysfunction.<sup>1,2<\/sup>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\nClick to visit the <a href=\"http:\/\/www.mydryeyes.com.au\">Product Website<\/a>\r\n\r\n&nbsp;\r\n\r\n<strong>NovaTears<sup>\u00ae<\/sup> is a PBS Listed Product<\/strong>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2022-09-19-at-4-55-02-pm\/\"><img class=\"aligncenter size-full wp-image-50278\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/Screen-Shot-2022-09-19-at-4.55.02-PM.png\" alt=\"\" width=\"2012\" height=\"142\" \/><\/a>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\n&nbsp;\r\n\r\n<sup>1.Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease \u2013 A Prospective, Multicenter Noninterventional Study.\u201d Journal of Ocular Pharmacology and Therapeutics 31 (8), 498-503(2015). 2. Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.\u201d Journal of Ocular Pharmacology and Therapeutics. 33(9), 678-685(2017). Sponsored by Novaliq GmbH.<\/sup>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nAFT Pharmaceuticals Pty Ltd, Sydney | ABN: 29105636413| Freephone: 1800 AFTPHARM | Freefax: 1800 041 026 Email: sydney.reception@aftpharm.com | Website: <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/NOVA_TEARS_Bottle_2000x1000_72dpi.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"3692","post_title":"CRYSTADERM","post_content":"Crystaderm\u00ae (Hydrogen Peroxide cream 1% w\/w, 10g and 15g) is a first aid antiseptic cream for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, burns and school sores (impetigo).\r\n\r\nCrystaderm\u00ae is a broad-spectrum, preservative-free antiseptic cream that slowly releases hydrogen peroxide from lipid crystals for effective protection against skin infection with no known bacterial resistance<sup>1<\/sup> unlike topical antibiotics. Hydrogen peroxide is a potent agent against many types of bacteria, some fungi, and viruses, that acts by destroying essential components of the cells of these organisms.\r\n\r\nCrystaderm\u00ae dries fast and adheres to both moist and dry areas, and doesn\u2019t stain skin, hands and fabric. A small amount of Crystaderm\u00ae goes a long way so can be applied sparingly, and the smooth, pearly white cream vanishes quickly on application.\r\n\r\nCrystaderm\u00ae 10g cream is a fully funded general sales medicine - available from pharmacies and supermarkets. Crystaderm\u00ae 15g is an unfunded medicine.\r\n\r\n<em>Contraindications:<\/em> Known hypersensitivity to any ingredient.\r\n\r\n<em>Precautions: <\/em>Use under medical guidance in pregnancy and breastfeeding. Avoid contact with the eyes. Do not use in the presence of iodine, permanganate and any other strong oxidising agents.\r\n\r\n<em>Adverse Effects:<\/em> Mild sensation of burning may be experienced for a short time after application.\r\n\r\n<em>Directions for use: <\/em>After cleansing the area, apply cream 2-3 times daily on affected area. A dry film will appear on the skin after application, which can be washed off with water.\r\n\r\n&nbsp;\r\n\r\nClick here to visit the <a href=\"https:\/\/crystaderm.co.nz\/\">Crystaderm website<\/a>\r\n\r\nClick here to view the Crystaderm\u00ae detail aid\r\n\r\nClick here to view Crystaderm\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/oNg9uWKfm2k\">First Aid video<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/tGINSugNu5I\">Acne video<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy for Treating Chronic Wounds, 2009, 49:1541\u20131549.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-10.00.13-PM.png","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"58350","post_title":"FEMME-TAB (30\/150)","post_content":"Available on the general schedule as an Unrestricted Benefit. Refer to PBS schedule for full information. Before prescribing, please review the full product information at <a href=\"http:\/\/www.aftpharm.co.au\/femmetab20100\">www.aftpharm.co.au\/femmetab20100<\/a> or <a href=\"http:\/\/www.afpharm.com\/femmetab30150\">www.afpharm.com\/femmetab30150<\/a> or on request from AFT Pharmaceuticals.\r\n\r\nFemme-Tab ED 30\/150 is a Prescription Only S4 medicine for use as oral contraception.\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\"><img class=\"size-full wp-image-45353 alignleft\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\" alt=\"\" width=\"250\" height=\"176\" \/><\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>FEMME-TAB ED 30\/150<\/strong>\r\n\r\nA high dose combination of Ethinyloestradiol 30 micrograms and Levonorgestrel 150 micrograms available on the PBS.\r\n\r\n28 x Film-coated Tablets\r\n\r\nAUST R 170389\r\n\r\n&nbsp;\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-PI.pdf\">Femme-tab 30.150 PI<\/a>\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-CMI.pdf\">Customer leaflet<\/a>\r\n\r\nClick to view Femme-Tab <a href=\"https:\/\/mysamples.com.au\/femme-tab-swatch-sets_h\/\">Swatch Sets<\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>PBS Information<\/strong>\r\n\r\nThese products are listed on the PBS as medicine for Oral Contraception.\r\n\r\n&nbsp;\r\n\r\n<strong>Product Mandatory statement<\/strong>\r\n\r\nS4 Prescription only medicine.\r\n\r\n&nbsp;\r\n\r\n<strong>Dosage<\/strong>\r\n\r\nOne tablet is to be taken daily. The tablets must be taken in the order directed on the package every day at about the same time. Daily tablet taking should be continuous for 28 consecutive days, starting with a tablet corresponding to that day of the week from the red section of the Femme-Tab pack. Each subsequent pack is started the day after the last tablet of the previous pack. Refer to insert for further information.\r\n\r\n&nbsp;\r\n\r\n<strong>Warnings<\/strong>\r\n\r\nProduct contains lactose.\r\n\r\nKeep out of reach of children.\r\n\r\nDo not use after the expiry date stated on the package.\r\n\r\nSee Minimum PI for further information.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot.jpg","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null},{"ID":"3957","post_title":"MAXIGESIC","post_content":"Developed in New Zealand, Maxigesic\u00ae is a unique, patented combination of paracetamol 500mg and ibuprofen 150mg that provides fast, effective double action relief for a wide range of pain symptoms, and also reduces inflammation and fever.\r\n\r\nAt maximum dosage, Maxigesic\u00ae is clinically proven to provide better, faster pain relief than paracetamol or ibuprofen alone<sup>1<\/sup>:\r\n<ul>\r\n \t<li>78% more effective relief than paracetamol alone<sup>1<\/sup><\/li>\r\n \t<li>36% more effective relief than ibuprofen alone<sup>1<\/sup><\/li>\r\n \t<li>Faster meaningful pain relief than paracetamol or ibuprofen alone<sup>1<\/sup><\/li>\r\n<\/ul>\r\nMaxigesic\u00ae also provides significantly more effective pain relief than paracetamol or ibuprofen alone within the first dosing period (6 hours)<sup>1<\/sup>, and is the only combination analgesic that provides the maximum recommended daily OTC dose of paracetamol 4000mg and ibuprofen 1200mg, if required (2 tablets, four times per day).\r\n\r\nMaxigesic\u00ae is also a well-tolerated combination for patients, with no more adverse events than paracetamol or ibuprofen alone<sup>2<\/sup>.\r\n\r\nMaxigesic\u00ae is indicated for the temporary relief of pain and reduction of fever and the discomfort associated with fever. It is suitable for the temporary relief of pain associated with headache, migraine headache, tension headache, toothache, dental procedures, backache, arthritis, rheumatic pain, period pain, muscular pain, tennis elbow, sinus pain, sore throat, and aches and pains associated with colds and flu.\r\n\r\nMaxigesic\u00ae is an unfunded medicine - available from pharmacies (10, 20, 50 and 100 tablets) and supermarkets (10 and 20 tablets).\r\n\r\n<em>Contraindications:<\/em> Hypersensitivity to any ingredient. Existing peptic ulceration or other stomach disorders, asthma, impaired kidney function or heart failure. Urticaria or rhinitis associated with aspirin or other NSAID\u2019s. Pregnancy except on doctor\u2019s advice. Do not use in the last trimester of pregnancy. Do not use in children under 12 years.\r\n\r\n<em>Precautions: <\/em>Do not combine with any other paracetamol or ibuprofen containing medications. Asthma, stomach ulcer, kidney disease, liver disease, heart failure, high blood pressure.\r\n\r\n<em>Adverse Effects:<\/em> Nausea, dyspepsia, rash, constipation, dizziness, oedema, tinnitis, headache, gastrointestinal bleeding (rare at OTC dose). Hepatic dysfunction and papillary necrosis may occur.\r\n\r\n<em>Interactions:<\/em> Anticoagulant medication, diuretics, lithium, methotrexate, or other medicines for pain relief.\r\n\r\n<em>Directions for use: <\/em>\r\n\r\nAdults and children over 12 years: Take 1 or 2 tablets every 4-6 hours, as required, up to a maximum of 8 tablets in 24 hours. Not recommended for children under 12 years of age.\r\n\r\n&nbsp;\r\n\r\nClick here to access the <a href=\"https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/m\/maxigesictab.pdf\">Maxigesic datasheet<\/a>\r\n\r\nClick here to visit the <a href=\"https:\/\/maxigesic.co.nz\/\">Maxigesic\u00ae website<\/a>\r\n\r\nClick here to view the Maxigesic\u00ae detail aid\r\n\r\nClick here to view Maxigesic\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/748yPa7vRTs\">Brand<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/txSmp6USzdc\">Back Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/GgVHJH5zb-I\">Headache<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/qoguNnEWhg8\">Joint Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/W_coLBBWHU0\">Period Pain #1<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/aB4DBvMiDF0\">Period Pain #2<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Daniels et al (2018). Result achieved in a trial of post-operative pain relief after removal of at least 2 wisdom teeth using MAXIGESIC\u00ae (Paracetamol 975mg\/Ibuprofen 292.5mg) compared with Paracetamol 975mg or Ibuprofen 292.5mg alone 4 times a day (Paracetamol 3900mg or Ibuprofen 1170mg per day). Study results assessed on the intent-to-treat (ITT) population with adjustment for the use of rescue medication. MAXIGESIC\u00ae 975\/292.5mg US combination is bioequivalent to MAXIGESIC\u00ae 1000\/300mg NZ combination at full dose (Aitken et al, 2018). Research sponsored by AFT Pharmaceuticals. 2. Aitken P, Stanescu I, Playne R, Zhang J, Frampton C and Atkinson HC (2019). \u201cAn Integrated Safety Analysis of Combined Acetaminophen and ibuprofen (MAXIGESIC\u00ae\/Combogesic\u00ae) in Adults\u201d, Journal of Pain Research 2019:12 621-634.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\nAFT Pharmaceuticals Ltd, Auckland\r\n\r\n<strong><em>Freephone:<\/em><\/strong> \u00a0\u00a0\u00a0 0800 423 823\r\n\r\n<strong><em>Freefax:<\/em><\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0800 423 874\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-9.55.50-PM.png","cat_name":"I would like to request further training on this product for me and\/or my staff.","slug":"i-would-like-to-request-further-training-on-this-product-for-me-and-or-my-staff","sku_code":null}],"rep-visit-info":[{"ID":"43716","post_title":"FERRO F TAB","post_content":"Each tablet contains Ferrous Fumerate 310mg (equivalent to elemental iron 100mg) + Folic Acid 350\u00b5g\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 2 Ferro-F-Tab tablets down to 1 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b><u><\/u>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-53-12-pm\/\"><img class=\"aligncenter size-full wp-image-43730\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.53.12-pm.png\" alt=\"\" width=\"536\" height=\"767\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-F-TAB-ANGLED.jpg","cat_name":"I would like a Rep to visit or provide more information about this product","slug":"rep-visit-info","sku_code":null},{"ID":"43715","post_title":"FERRO TAB","post_content":"<!--more-->Each tablet contains Ferrous Fumerate 200mg (equivalent to 67.5mg elemental iron) and does not include any other vitamins or minerals that can affect absorption<u>\r\n<\/u>\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 3 Ferro-Tab tablets down to 2 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-43-53-pm\/\"><img class=\"aligncenter size-full wp-image-43729\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.43.53-pm.png\" alt=\"\" width=\"504\" height=\"665\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-TAB-ANGLED.jpg","cat_name":"I would like a Rep to visit or provide more information about this product","slug":"rep-visit-info","sku_code":null},{"ID":"58350","post_title":"FEMME-TAB (30\/150)","post_content":"Available on the general schedule as an Unrestricted Benefit. Refer to PBS schedule for full information. Before prescribing, please review the full product information at <a href=\"http:\/\/www.aftpharm.co.au\/femmetab20100\">www.aftpharm.co.au\/femmetab20100<\/a> or <a href=\"http:\/\/www.afpharm.com\/femmetab30150\">www.afpharm.com\/femmetab30150<\/a> or on request from AFT Pharmaceuticals.\r\n\r\nFemme-Tab ED 30\/150 is a Prescription Only S4 medicine for use as oral contraception.\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\"><img class=\"size-full wp-image-45353 alignleft\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\" alt=\"\" width=\"250\" height=\"176\" \/><\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>FEMME-TAB ED 30\/150<\/strong>\r\n\r\nA high dose combination of Ethinyloestradiol 30 micrograms and Levonorgestrel 150 micrograms available on the PBS.\r\n\r\n28 x Film-coated Tablets\r\n\r\nAUST R 170389\r\n\r\n&nbsp;\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-PI.pdf\">Femme-tab 30.150 PI<\/a>\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-CMI.pdf\">Customer leaflet<\/a>\r\n\r\nClick to view Femme-Tab <a href=\"https:\/\/mysamples.com.au\/femme-tab-swatch-sets_h\/\">Swatch Sets<\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>PBS Information<\/strong>\r\n\r\nThese products are listed on the PBS as medicine for Oral Contraception.\r\n\r\n&nbsp;\r\n\r\n<strong>Product Mandatory statement<\/strong>\r\n\r\nS4 Prescription only medicine.\r\n\r\n&nbsp;\r\n\r\n<strong>Dosage<\/strong>\r\n\r\nOne tablet is to be taken daily. The tablets must be taken in the order directed on the package every day at about the same time. Daily tablet taking should be continuous for 28 consecutive days, starting with a tablet corresponding to that day of the week from the red section of the Femme-Tab pack. Each subsequent pack is started the day after the last tablet of the previous pack. Refer to insert for further information.\r\n\r\n&nbsp;\r\n\r\n<strong>Warnings<\/strong>\r\n\r\nProduct contains lactose.\r\n\r\nKeep out of reach of children.\r\n\r\nDo not use after the expiry date stated on the package.\r\n\r\nSee Minimum PI for further information.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot.jpg","cat_name":"I would like a Rep to visit or provide more information about this product","slug":"rep-visit-info","sku_code":null}],"more-information":[{"ID":"45376","post_title":"a2 MILK\u2122 FULL CREAM UHT","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/a2milk_hcp-booklet_mar21\/\">a2 Milk HCP Booklet<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/a2nutrition4professionals.com.au\/\">HCP website<\/a>\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45381\" rel=\"attachment wp-att-45381\"><img class=\"alignleft size-full wp-image-45381\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.21.40-pm.png\" alt=\"\" width=\"743\" height=\"1052\" \/><\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45382\" rel=\"attachment wp-att-45382\"><img class=\"alignleft size-full wp-image-45382\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.22.04-pm.png\" alt=\"\" width=\"745\" height=\"783\" \/><\/a>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/UHT-packshot.png","cat_name":"I would like more information about this product.","slug":"more-information","sku_code":null},{"ID":"55902","post_title":"SINUPRET\u00ae","post_content":"[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/07\/Sinupret23-ADULTS-1920x1080_05-2.mp4\"][\/video]\r\n\r\n&nbsp;\r\n\r\nClick to download the <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/07\/Sinupret-Detailer-A5-Brochure-FINAL-SP23029.pdf\">Sinupret Detailer<\/a>\r\n<p class=\"p1\">Sinupret\u00ae is available as:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Sinupret\u00ae forte, coated tablets for adults and children 12 years and over<\/li>\r\n \t<li class=\"p1\">Sinupret\u00ae Syrup, an oral liquid for adults and children 2 years and over<\/li>\r\n<\/ul>\r\nSinupret\u00ae, with its unique 5-plant formula has secretolytic and anti-inflammatory effects, helping to clear nasal congestion and reduce the duration of sinus headaches.\r\n<p class=\"p1\">Sinupret\u00ae forte is clinically proven to relieve symptoms associated with sinusitis, when combined with antibiotics and nasal decongestant sprays.<sup>1 <\/sup>Similarly, Sinupret\u00ae Syrup also offers clinically proven sinusitis relief in children.<sup>2-4<\/sup><\/p>\r\n<p class=\"p1\">It is the No. 1 market leader in German-speaking Europe (Germany, Austria and Switzerland).<sup>5<\/sup><\/p>\r\n<p class=\"p1\">Sinupret\u00ae loosens mucus, opens the nose and clears the head. It helps restore mucociliary clearance by:<\/p>\r\n\r\n<ul>\r\n \t<li>Hydrating the respiratory epithelium via improved chloride secretion and,<\/li>\r\n \t<li>Promoting the break up of secretions - a process known as secretolytic.<\/li>\r\n<\/ul>\r\n<p class=\"p1\">Sinupret\u00ae forte - active substances:<\/p>\r\n<p class=\"p1\">Each coated tablet contains:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Gentiana lutea root (gentian root) powder 12 mg<\/li>\r\n \t<li class=\"p1\">Primula veris (German Medicinal Product Codex) flower (cowslip) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Rumex crispus herb (sorrel) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Sambucus nigra flower (elder flower) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Verbena officinalis herb (vervain) powder 36 mg<\/li>\r\n \t<li class=\"p1\"><b>Contains:<\/b> Sugars and lactose.<\/li>\r\n<\/ul>\r\n<p class=\"p1\">Sinupret\u00ae Syrup - active substances:<\/p>\r\n<p class=\"p1\">1 mL of Sinupret\u00ae Syrup contains 0.417 g of herbal extract equivalent to dry:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Gentiana lutea root 0.85 mg<\/li>\r\n \t<li class=\"p1\">Primula veris (German Medicinal Product Codex) flower 2.54 mg<\/li>\r\n \t<li class=\"p1\">Rumex crispus herb 2.54 mg<\/li>\r\n \t<li class=\"p1\">Sambucus nigra flower 2.54 mg<\/li>\r\n \t<li class=\"p1\">Verbena officinalis herb 2.54 mg<\/li>\r\n \t<li class=\"p1\"><b>Contains: <\/b>cherry flavour, ethanol, liquid maltitol.<\/li>\r\n<\/ul>\r\nFor further information visit <a href=\"http:\/\/www.sinupret.com.au\">the Product website<\/a>\r\n\r\nReferences*\r\n<p class=\"p1\">1. Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed. 2006; 13(2):78\u201387. (Partly funded by a grant from Bionorica, Neumarkt, Germany)<\/p>\r\n<p class=\"p1\">2. Virgin F et al. The bioflavonoid compound, Sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010;120(5):1051-6.<\/p>\r\n<p class=\"p1\">3. Popovich V and Beketova H. Results of a randomised controlled study on the efficacy of a combination of saline irrigation and Sinupret syrup phytopreparation in the treatment of acute viral rhinosinusitis in children aged 6 to 11 years. Clinical Phytoscience 2018;4:21. https:\/\/doi.org\/10.1186\/s40816-018-0082-y.<\/p>\r\n<p class=\"p1\">4. Popovich V and Koshel I. Sinupret\u00ae as add-on therapy to saline irrigation for children with acute post-viral rhinosinusitis. Clinical Phytoscience 2017;3:10. DOI 10.1186\/s40816-017-0047-6.<\/p>\r\n<p class=\"p1\">5. QVIA. Pharmacy sell-out in euro on retail price level and sales in units, 2021; CH:IQVIA. Sales in euro on ex-manufacturer price level and sales in units, YTD 06.2021; AT:IQVIA, Pharmacy sell-out in euro on retail price level and sales in units. 2021.<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/05\/Sinupret-Forte-Group-Image.png","cat_name":"I would like more information about this product.","slug":"more-information","sku_code":null}],"representative-contact":[{"ID":"47809","post_title":"SLINDA\u00ae","post_content":"Slinda<sup>\u00ae<\/sup> is a progestogen-only contraceptive pill with similar efficacy to combined oral contraceptives, and a 24-hour missed pill window.<sup>1-4<\/sup> In the pivotal clinical trial programme, Slinda<sup>\u00ae<\/sup> resulted in 99% contraceptive efficacy (Pearl Index 0.73) in a broad patient population that included women with multiple cardiovascular risk factors, including smoking, obesity, and a family history of venous thromboembolism.<sup>1-4<\/sup>\r\n\r\nProgestogen-only contraceptives such as Slinda<sup>\u00ae<\/sup> may be more suitable than combined oral contraceptives for a broad range of women, particularly for those who want to avoid estrogen-related risks and side effects.<sup>4,5<\/sup>\r\n\r\nImportantly, Slinda<sup>\u00ae<\/sup> can be safely used in breastfeeding mothers.<sup>1,5<\/sup> Plus, Slinda<sup>\u00ae<\/sup> is simple to use, easy to start and follows a 24 + 4 dosing regimen.<sup>1<\/sup>\r\n<p class=\"p1\">Please review Product Information before prescribing.<\/p>\r\n<p class=\"p1\">The Product Information can be accessed <a href=\"https:\/\/besins-healthcare.com.au\/healthcare-professionals\/product-information\/\">here<\/a>\u00a0or telephone 1800 BESINS (237 467).<\/p>\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\/\"><strong>CLICK HERE<\/strong><\/a> FOR BESINS HEALTHCARE WEBSITE\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-e1630471245894.png\"><img class=\"aligncenter size-medium wp-image-43130\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-300x68.png\" alt=\"\" width=\"300\" height=\"68\" \/><\/a>\r\n<p class=\"p1\">Minimum Product Information Slinda (drospirenone 4 mg) Indication: Contraception Contraindications: active venous thromboembolic disorder; presence or history of severe hepatic disease with abnormal liver function values; severe renal insufficiency or acute renal failure; known or suspected sex-steroid sensitive malignancies; undiagnosed vaginal bleeding; hypersensitivity to active substance or any excipients. Clinically significant precautions: a complete medical history should be taken and pregnancy excluded, patients should be counselled that contraceptives do not protect against HIV or STIs; efficacy can be reduced with missed pills and gastrointestinal disturbances; hyperkalaemia (monitor serum potassium levels in patients presenting with renal insufficiency and pre-treatment potassium in upper reference range); risk of stroke and VTE may be slightly increased with progestogen-only preparations; discontinue Slinda with pregnancy, symptoms of thrombosis, jaundice, sustained hypertension; consider discontinuation with prolonged immobilisation; decreased estradiol levels may affect bone metabolism; breast cancer risk may be similar to that associated with COC use; rare cases of liver tumours with hormonal contraceptive use; new amenorrhea or abdominal pain may indicate ectopic pregnancy; monitor for altered insulin and glucose tolerance in diabetic patients, mood and depressive symptoms; changes in menstrual bleeding and chloasma may occur. Clinically significant interactions: enzyme-inducing drugs can lead to contraceptive failure and\/or breakthrough bleeding, patients on long-term treatment are advised not to use Slinda; certain medications increase clearance of contraceptive hormones (e.g. barbiturates, bosentan, carbamazepine, phenytoin, rifampicin); HIV\/HCV medications can alter progestin concentrations; CYP3A4 enzyme inhibitors such as azole antifungals, verapamil, macrolides, diltiazem and grapefruit juice can increase plasma progestogen concentrations; Slinda may affect cytochrome P450 metabolism of other active substances (e.g. cyclosporine, lamotrigine); monitor for hyperkalaemia with use of potassium-sparing medicines. Very common and common adverse effects: acne, changes in menstrual bleeding (metrorrhagia, vaginal haemorrhage, dysmenorrhea, menstruation irregular), headache, breast pain, libido and mood changes, nausea, abdominal pain, weight increased (see full PI). Dosage and method of use: tablets must be taken orally the same time each day without a break in daily tablet intake; 7 days of uninterrupted tablet intake is required to attain adequate contraception; contraceptive protection is not reduced if a patient is less than 24 hours late in tablet intake; management of missed tablets (more than 24 hours late) is dependent on stage of menstrual cycle (see full PI); consider additional contraceptive measures with gastrointestinal disturbances.<\/p>\r\n<strong>References: <\/strong>\r\n<ol>\r\n \t<li>Slinda<sup>\u00ae<\/sup> (drospirenone) Product Information, accessed July 2021.<\/li>\r\n \t<li>Archer D <em>et al. Contraception<\/em> 2015;92(5):439-44.<\/li>\r\n \t<li>Palacios S <em>et al. Acta Obstet Gynecol Scand<\/em> 2019;98(12):1549-57.<\/li>\r\n \t<li>Palacios S <em>et al. Eur J Contracept Reprod Health Care<\/em> 2020;25(3):221-27.<\/li>\r\n \t<li>Family Planning New South Wales, Family Planning Victoria and True Relationships and Reproductive Health. Contraception: An Australian Clinical Practice Handbook, 4<sup>th<\/sup> edition. Ashfield NSW, 2016.<\/li>\r\n<\/ol>\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n\r\nSlinda<sup>\u00ae<\/sup> is a registered trademark of Chemo Research S.L.\r\n\r\nBesins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473.\u00a0<a href=\"http:\/\/www.besins-healthcare.com.au\/\">www.besins-healthcare.com.au<\/a>\r\n\r\nSLI-1001","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/07\/Slinda-box.jpeg","cat_name":"I would like a Representative to contact me","slug":"representative-contact","sku_code":null},{"ID":"50181","post_title":"NOVATEARS\u00ae","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/31942-novatears-gpdetailer-a4-singlepage-f\/\">NovaTears Detail aid<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/mysamples.com.au\/34470-consumer-flyer-au-a5-148x210-v1\/\">Patient Flyer<\/a>\r\n\r\nView the NovaTears<sup>\u00ae<\/sup> Product Information video below.\r\n\r\n<iframe title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/tpYqOwZBI24\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nNovaTears\u00ae is a patented preservative-free eye lubricant, which acts as a lipid layer substitute and evaporative barrier for improved tear film stability and quality.\r\n\r\nPreservative, Phosphate &amp; Aqueous Free. Spreads quickly &amp; easily on the eye\r\n\r\nPleasant, warm silky feeling with no stinging or blurring\r\n\r\nClinically validated with significant improvements in signs &amp; symptoms for patients with Evaporative Dry Eye Disease &amp; Meibomian Gland Dysfunction.<sup>1,2<\/sup>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\nClick to visit the <a href=\"http:\/\/www.mydryeyes.com.au\">Product Website<\/a>\r\n\r\n&nbsp;\r\n\r\n<strong>NovaTears<sup>\u00ae<\/sup> is a PBS Listed Product<\/strong>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2022-09-19-at-4-55-02-pm\/\"><img class=\"aligncenter size-full wp-image-50278\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/Screen-Shot-2022-09-19-at-4.55.02-PM.png\" alt=\"\" width=\"2012\" height=\"142\" \/><\/a>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\n&nbsp;\r\n\r\n<sup>1.Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease \u2013 A Prospective, Multicenter Noninterventional Study.\u201d Journal of Ocular Pharmacology and Therapeutics 31 (8), 498-503(2015). 2. Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.\u201d Journal of Ocular Pharmacology and Therapeutics. 33(9), 678-685(2017). Sponsored by Novaliq GmbH.<\/sup>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nAFT Pharmaceuticals Pty Ltd, Sydney | ABN: 29105636413| Freephone: 1800 AFTPHARM | Freefax: 1800 041 026 Email: sydney.reception@aftpharm.com | Website: <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/NOVA_TEARS_Bottle_2000x1000_72dpi.jpg","cat_name":"I would like a Representative to contact me","slug":"representative-contact","sku_code":null},{"ID":"31227","post_title":"UTROGESTAN\u00ae","post_content":"<p class=\"p1\">Luteal Phase Support<sup>1<\/sup><\/p>\r\n<p class=\"p1\">Utrogestan is indicated for use in luteal phase support during Assisted Reproductive Treatment (ART) cycles and is reimbursed for the first two weeks following embryo transfer<sup>2<\/sup>.<\/p>\r\n<p class=\"p1\">Utrogestan is available as 200mg soft vaginal capsules in packs of 42 capsules (two weeks supply).<\/p>\r\n<p class=\"p1\">Dosage is three times daily, administered vaginally, from the day of embryo transfer until at least the 7th week of pregnancy and no later than the 12th week of pregnancy.<\/p>\r\n<p class=\"p1\">Utrogestan (micronised progesterone) is TGA-approved for prevention of preterm birth, in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix \u226425 mm) and\/or a history of spontaneous preterm birth.<sup>1<\/sup> Compared to placebo, vaginal progesterone significantly reduces the risk of preterm birth and improves perinatal outcomes in women with singleton pregnancy and a short cervix, with proven maternal and neonatal tolerability.<sup>1, 3-5<\/sup> Utrogestan vaginal capsules are administered once-daily, are easy to insert and readily absorbed.<sup>1<\/sup><\/p>\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li class=\"p1\">Utrogestan<sup>\u00ae<\/sup> (micronised progesterone) Product Information, updated 13 November 2019.<\/li>\r\n \t<li>Pharmaceutical Benefits Scheme\u00a0Available at <a href=\"https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines\">https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines<\/a><\/li>\r\n \t<li class=\"p1\">Romero R et al. Am J Obstet Gynaecol 2018;218(2):161-80.<\/li>\r\n \t<li class=\"p1\">Norman JE et al. Lancet 2016;387:2106-16.<\/li>\r\n \t<li class=\"p1\">Fonseca EB et al. N Engl J Med 2007;357:462-9.<\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Utrogestan<sup>\u00ae<\/sup> is a registered trademark of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\n<p class=\"p1\">UTR0514<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Utrogestan-Packaging-Images_Utrogestan-Pack_Caps-1.jpg","cat_name":"I would like a Representative to contact me","slug":"representative-contact","sku_code":null}],"patient-info-slinda":[{"ID":"47809","post_title":"SLINDA\u00ae","post_content":"Slinda<sup>\u00ae<\/sup> is a progestogen-only contraceptive pill with similar efficacy to combined oral contraceptives, and a 24-hour missed pill window.<sup>1-4<\/sup> In the pivotal clinical trial programme, Slinda<sup>\u00ae<\/sup> resulted in 99% contraceptive efficacy (Pearl Index 0.73) in a broad patient population that included women with multiple cardiovascular risk factors, including smoking, obesity, and a family history of venous thromboembolism.<sup>1-4<\/sup>\r\n\r\nProgestogen-only contraceptives such as Slinda<sup>\u00ae<\/sup> may be more suitable than combined oral contraceptives for a broad range of women, particularly for those who want to avoid estrogen-related risks and side effects.<sup>4,5<\/sup>\r\n\r\nImportantly, Slinda<sup>\u00ae<\/sup> can be safely used in breastfeeding mothers.<sup>1,5<\/sup> Plus, Slinda<sup>\u00ae<\/sup> is simple to use, easy to start and follows a 24 + 4 dosing regimen.<sup>1<\/sup>\r\n<p class=\"p1\">Please review Product Information before prescribing.<\/p>\r\n<p class=\"p1\">The Product Information can be accessed <a href=\"https:\/\/besins-healthcare.com.au\/healthcare-professionals\/product-information\/\">here<\/a>\u00a0or telephone 1800 BESINS (237 467).<\/p>\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\/\"><strong>CLICK HERE<\/strong><\/a> FOR BESINS HEALTHCARE WEBSITE\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-e1630471245894.png\"><img class=\"aligncenter size-medium wp-image-43130\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-300x68.png\" alt=\"\" width=\"300\" height=\"68\" \/><\/a>\r\n<p class=\"p1\">Minimum Product Information Slinda (drospirenone 4 mg) Indication: Contraception Contraindications: active venous thromboembolic disorder; presence or history of severe hepatic disease with abnormal liver function values; severe renal insufficiency or acute renal failure; known or suspected sex-steroid sensitive malignancies; undiagnosed vaginal bleeding; hypersensitivity to active substance or any excipients. Clinically significant precautions: a complete medical history should be taken and pregnancy excluded, patients should be counselled that contraceptives do not protect against HIV or STIs; efficacy can be reduced with missed pills and gastrointestinal disturbances; hyperkalaemia (monitor serum potassium levels in patients presenting with renal insufficiency and pre-treatment potassium in upper reference range); risk of stroke and VTE may be slightly increased with progestogen-only preparations; discontinue Slinda with pregnancy, symptoms of thrombosis, jaundice, sustained hypertension; consider discontinuation with prolonged immobilisation; decreased estradiol levels may affect bone metabolism; breast cancer risk may be similar to that associated with COC use; rare cases of liver tumours with hormonal contraceptive use; new amenorrhea or abdominal pain may indicate ectopic pregnancy; monitor for altered insulin and glucose tolerance in diabetic patients, mood and depressive symptoms; changes in menstrual bleeding and chloasma may occur. Clinically significant interactions: enzyme-inducing drugs can lead to contraceptive failure and\/or breakthrough bleeding, patients on long-term treatment are advised not to use Slinda; certain medications increase clearance of contraceptive hormones (e.g. barbiturates, bosentan, carbamazepine, phenytoin, rifampicin); HIV\/HCV medications can alter progestin concentrations; CYP3A4 enzyme inhibitors such as azole antifungals, verapamil, macrolides, diltiazem and grapefruit juice can increase plasma progestogen concentrations; Slinda may affect cytochrome P450 metabolism of other active substances (e.g. cyclosporine, lamotrigine); monitor for hyperkalaemia with use of potassium-sparing medicines. Very common and common adverse effects: acne, changes in menstrual bleeding (metrorrhagia, vaginal haemorrhage, dysmenorrhea, menstruation irregular), headache, breast pain, libido and mood changes, nausea, abdominal pain, weight increased (see full PI). Dosage and method of use: tablets must be taken orally the same time each day without a break in daily tablet intake; 7 days of uninterrupted tablet intake is required to attain adequate contraception; contraceptive protection is not reduced if a patient is less than 24 hours late in tablet intake; management of missed tablets (more than 24 hours late) is dependent on stage of menstrual cycle (see full PI); consider additional contraceptive measures with gastrointestinal disturbances.<\/p>\r\n<strong>References: <\/strong>\r\n<ol>\r\n \t<li>Slinda<sup>\u00ae<\/sup> (drospirenone) Product Information, accessed July 2021.<\/li>\r\n \t<li>Archer D <em>et al. Contraception<\/em> 2015;92(5):439-44.<\/li>\r\n \t<li>Palacios S <em>et al. Acta Obstet Gynecol Scand<\/em> 2019;98(12):1549-57.<\/li>\r\n \t<li>Palacios S <em>et al. Eur J Contracept Reprod Health Care<\/em> 2020;25(3):221-27.<\/li>\r\n \t<li>Family Planning New South Wales, Family Planning Victoria and True Relationships and Reproductive Health. Contraception: An Australian Clinical Practice Handbook, 4<sup>th<\/sup> edition. Ashfield NSW, 2016.<\/li>\r\n<\/ol>\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n\r\nSlinda<sup>\u00ae<\/sup> is a registered trademark of Chemo Research S.L.\r\n\r\nBesins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473.\u00a0<a href=\"http:\/\/www.besins-healthcare.com.au\/\">www.besins-healthcare.com.au<\/a>\r\n\r\nSLI-1001","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/07\/Slinda-box.jpeg","cat_name":"I would like patient information on Slinda","slug":"patient-info-slinda","sku_code":null}],"slinda-counselling-guide":[{"ID":"47809","post_title":"SLINDA\u00ae","post_content":"Slinda<sup>\u00ae<\/sup> is a progestogen-only contraceptive pill with similar efficacy to combined oral contraceptives, and a 24-hour missed pill window.<sup>1-4<\/sup> In the pivotal clinical trial programme, Slinda<sup>\u00ae<\/sup> resulted in 99% contraceptive efficacy (Pearl Index 0.73) in a broad patient population that included women with multiple cardiovascular risk factors, including smoking, obesity, and a family history of venous thromboembolism.<sup>1-4<\/sup>\r\n\r\nProgestogen-only contraceptives such as Slinda<sup>\u00ae<\/sup> may be more suitable than combined oral contraceptives for a broad range of women, particularly for those who want to avoid estrogen-related risks and side effects.<sup>4,5<\/sup>\r\n\r\nImportantly, Slinda<sup>\u00ae<\/sup> can be safely used in breastfeeding mothers.<sup>1,5<\/sup> Plus, Slinda<sup>\u00ae<\/sup> is simple to use, easy to start and follows a 24 + 4 dosing regimen.<sup>1<\/sup>\r\n<p class=\"p1\">Please review Product Information before prescribing.<\/p>\r\n<p class=\"p1\">The Product Information can be accessed <a href=\"https:\/\/besins-healthcare.com.au\/healthcare-professionals\/product-information\/\">here<\/a>\u00a0or telephone 1800 BESINS (237 467).<\/p>\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\/\"><strong>CLICK HERE<\/strong><\/a> FOR BESINS HEALTHCARE WEBSITE\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-e1630471245894.png\"><img class=\"aligncenter size-medium wp-image-43130\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-300x68.png\" alt=\"\" width=\"300\" height=\"68\" \/><\/a>\r\n<p class=\"p1\">Minimum Product Information Slinda (drospirenone 4 mg) Indication: Contraception Contraindications: active venous thromboembolic disorder; presence or history of severe hepatic disease with abnormal liver function values; severe renal insufficiency or acute renal failure; known or suspected sex-steroid sensitive malignancies; undiagnosed vaginal bleeding; hypersensitivity to active substance or any excipients. Clinically significant precautions: a complete medical history should be taken and pregnancy excluded, patients should be counselled that contraceptives do not protect against HIV or STIs; efficacy can be reduced with missed pills and gastrointestinal disturbances; hyperkalaemia (monitor serum potassium levels in patients presenting with renal insufficiency and pre-treatment potassium in upper reference range); risk of stroke and VTE may be slightly increased with progestogen-only preparations; discontinue Slinda with pregnancy, symptoms of thrombosis, jaundice, sustained hypertension; consider discontinuation with prolonged immobilisation; decreased estradiol levels may affect bone metabolism; breast cancer risk may be similar to that associated with COC use; rare cases of liver tumours with hormonal contraceptive use; new amenorrhea or abdominal pain may indicate ectopic pregnancy; monitor for altered insulin and glucose tolerance in diabetic patients, mood and depressive symptoms; changes in menstrual bleeding and chloasma may occur. Clinically significant interactions: enzyme-inducing drugs can lead to contraceptive failure and\/or breakthrough bleeding, patients on long-term treatment are advised not to use Slinda; certain medications increase clearance of contraceptive hormones (e.g. barbiturates, bosentan, carbamazepine, phenytoin, rifampicin); HIV\/HCV medications can alter progestin concentrations; CYP3A4 enzyme inhibitors such as azole antifungals, verapamil, macrolides, diltiazem and grapefruit juice can increase plasma progestogen concentrations; Slinda may affect cytochrome P450 metabolism of other active substances (e.g. cyclosporine, lamotrigine); monitor for hyperkalaemia with use of potassium-sparing medicines. Very common and common adverse effects: acne, changes in menstrual bleeding (metrorrhagia, vaginal haemorrhage, dysmenorrhea, menstruation irregular), headache, breast pain, libido and mood changes, nausea, abdominal pain, weight increased (see full PI). Dosage and method of use: tablets must be taken orally the same time each day without a break in daily tablet intake; 7 days of uninterrupted tablet intake is required to attain adequate contraception; contraceptive protection is not reduced if a patient is less than 24 hours late in tablet intake; management of missed tablets (more than 24 hours late) is dependent on stage of menstrual cycle (see full PI); consider additional contraceptive measures with gastrointestinal disturbances.<\/p>\r\n<strong>References: <\/strong>\r\n<ol>\r\n \t<li>Slinda<sup>\u00ae<\/sup> (drospirenone) Product Information, accessed July 2021.<\/li>\r\n \t<li>Archer D <em>et al. Contraception<\/em> 2015;92(5):439-44.<\/li>\r\n \t<li>Palacios S <em>et al. Acta Obstet Gynecol Scand<\/em> 2019;98(12):1549-57.<\/li>\r\n \t<li>Palacios S <em>et al. Eur J Contracept Reprod Health Care<\/em> 2020;25(3):221-27.<\/li>\r\n \t<li>Family Planning New South Wales, Family Planning Victoria and True Relationships and Reproductive Health. Contraception: An Australian Clinical Practice Handbook, 4<sup>th<\/sup> edition. Ashfield NSW, 2016.<\/li>\r\n<\/ol>\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n\r\nSlinda<sup>\u00ae<\/sup> is a registered trademark of Chemo Research S.L.\r\n\r\nBesins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473.\u00a0<a href=\"http:\/\/www.besins-healthcare.com.au\/\">www.besins-healthcare.com.au<\/a>\r\n\r\nSLI-1001","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/07\/Slinda-box.jpeg","cat_name":"I would like a Slinda counselling guide","slug":"slinda-counselling-guide","sku_code":null}],"outofstock":[{"ID":"60218","post_title":"Novalac Constipation Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Constipation<\/strong> is specifically formulated to provide a balanced blend of nutrients to help soften stools, increase stool frequency, and relieve pain and discomfort.<sup>1-4<\/sup>\r\n\r\nKey benefits of Novalac Constipation:\r\n<ul>\r\n \t<li>91.6% of cases of infant constipation resolved within 7 days<sup>1<\/sup><\/li>\r\n \t<li>Helps manage constipation without the use of laxatives while giving babies essential nutrients.<sup>2-4<\/sup><\/li>\r\n \t<li>Novalac Constipation has been shown to significantly:\r\n<ul>\r\n \t<li>increase the water content of stools<sup>2<\/sup><\/li>\r\n \t<li>improve stool consistency and frequency<sup>1-4<\/sup><\/li>\r\n \t<li>reduce pain and discomfort with defecation<sup>1-3<\/sup><\/li>\r\n \t<li>reduce the need for manual assistance with defecation<sup>1,2<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Shortens intestinal transit time by increasing the osmotic load through a specially formulated combination of:\r\n<ul>\r\n \t<li>increased lactose (100% of carbohydrates) - produces an osmotic effect and may create a prebiotic effect when metabolised in the colon to help stimulate bowel movements<sup>1-3<\/sup><\/li>\r\n \t<li>increased magnesium to help increase water content<sup>1,4<\/sup><\/li>\r\n \t<li>an optimal calcium to phosphorus ratio of 2:1 which helps soften stools<sup>4-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Information-and-Evidence-NOV-08668-E0726.pdf\">Novalac Constipation Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Nutritional-Information.pdf\">Novalac Constipation Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li style=\"list-style-type: none;\">\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol 2008;14(2):248\u2013254.<\/li>\r\n \t<li>Infante DD, et al. Nut Journal. 2011;10:55.<\/li>\r\n \t<li>Le Luyer B, et al. RIP 2002; Tome XXXI;316:5\u20138. 33.<\/li>\r\n \t<li>Benninga MA, et al. Pediatr Gastroenterol Hepatol Nutr 2019;22(3):270281.<\/li>\r\n \t<li>Kesavelu D, et al. Clin Ep &amp; Glob Health 6. 2018;5\u20139.<\/li>\r\n \t<li>Khinchi M, et al. J Pediatr Gastroenterol &amp; Nutr. 1999;28(5):591.<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Constip_PackShot.jpg","cat_name":"outofstock","slug":"outofstock","sku_code":null},{"ID":"60224","post_title":"Novalac Reflux Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Reflux<\/strong> specialty infant formula is specifically formulated to help resolve reflux symptoms in infants, leading to a significant reduction in regurgitations, decreased time for bottle feeding, and increased volume of feeds.<sup>1<\/sup>\r\n\r\nKey benefits of Novalac Reflux:\r\n<ul>\r\n \t<li>81% of reflux case in infants resolved within 6 days<sup>1<\/sup><\/li>\r\n \t<li>Novalac Reflux has been shown to:\r\n<ul>\r\n \t<li>significantly reduce frequency and intensity of regurgitations and exposure of the oesophageal mucosa to acid.<sup>2<\/sup><\/li>\r\n \t<li>significantly increase feeding volume, gastric emptying and weight gain.<sup>3<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Thickens in the stomach, not the bottle, so it is easy for baby to drink and helps the feed stay down.<sup>1<\/sup><\/li>\r\n \t<li>Casein-dominant formula which helps prevent regurgitation and, in conjunction with specially treated cornstarch, encourages gastric emptying.<sup>1,3<\/sup><\/li>\r\n \t<li>Contains cornstarch with a high level of amylopectin for ease of digestion.<sup>2,4,5<\/sup><\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Product-Information-and-Evidence.pdf\">Novalac Reflux Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Nutritional-Information.pdf\">Novalac Reflux Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008;14(2):248\u201354.<\/li>\r\n \t<li>Xinias I, et al. Dig Liver Dis. 2005;37(1):23\u201327.<\/li>\r\n \t<li>Chao HC, et al. Dis Esophagus. 2007;20(2):155-60.<\/li>\r\n \t<li>Ketthaisong, et al. J Food Sci Technol, 2015; 52, 6529\u20136537.<\/li>\r\n \t<li>Lin A, et al. Molecules, 2017;22, 1526<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Reflux_PackShot.jpg","cat_name":"outofstock","slug":"outofstock","sku_code":null},{"ID":"60228","post_title":"Novalac Colic Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Colic<\/strong> has been scientifically formulated for infants with colic and associated symptoms such as gas and bloating.\r\n\r\nKey benefits of Novalac Colic:\r\n<ul>\r\n \t<li>87.6% of cases of colic in infants were shown to be resolved within 8 days<sup>1<\/sup><\/li>\r\n \t<li>Has been shown to significantly reduce gas, intestinal bloating and crying<sup>1,2<\/sup><\/li>\r\n \t<li>Contains easily digestible maltodextrin (70% of total carbohydrates) and a reduced proportion of lactose (30% of total carbohydrates) to reduce the risk of excessive gas which may be caused by the malabsorption of\u00a0lactose in the colon.<sup>2,3<\/sup><\/li>\r\n \t<li>Contains a Casein: Whey ratio of 40:60 to ease digestive discomfort to help infants to settle.<sup>4,5<\/sup><\/li>\r\n \t<li>Manages colic whilst feeding and nourishing baby with essential vitamins and minerals.<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Information-and-Evidence-NOV-08669-E0726.pdf\">Novalac Colic Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Nutritional-Information.pdf\">Novalac Colic Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\nNot suitable for general use and should be used under medical supervision.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008; 14(2):248\u201354.<\/li>\r\n \t<li>Infante DD, et al. World J Gastroenterol. 2011;17(16):2104\u20138.<\/li>\r\n \t<li>Hofman DL, et al. Crit Rev Food Sci Nutr. 2016; 56(12):2091\u2013100.<\/li>\r\n \t<li>Martin CR, et al. Nutrients. 2016; 8(5):279.<\/li>\r\n \t<li>Rafiee Tari N, et al. J Dairy Sci 2018;101(4): 2851\u201361.<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Colic_PackShot.jpg","cat_name":"outofstock","slug":"outofstock","sku_code":null},{"ID":"42837","post_title":"Novalac Allergy Premium Infant Formula Powder 800g","post_content":"<strong>NOVALAC Allergy<\/strong> has been scientifically formulated from protein sourced from rice, for babies unable to tolerate cow\u2019s milk formula or with a confirmed cow\u2019s milk protein allergy (CMPA). Novalac Allergy is also suitable for lactose intolerant babies.\r\n\r\nKey benefits of Novalac Allergy:\r\n<ul>\r\n \t<li><strong>The Australasian Society of Clinical Immunology and Allergy (ASCIA) recommends rice protein-based infant formula as a first choice for infants with CMPA when breastfeeding is not possible<sup>1*<\/sup><\/strong>\r\n<ul>\r\n \t<li><strong>Novalac Allergy is the\u00a0<u>only<\/u> rice protein based infant formula in the ASCIA guidelines that has product specific hypo-allergenicity and growth studies.<sup>1<\/sup><\/strong><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Hypoallergenic - Tolerated by &gt;90% of infants with confirmed CMPA<sup>2-4<\/sup>\r\n<ul>\r\n \t<li>Reduces allergy symptoms associated with CMPA including regurgitation, eczema, diarrhoea and constipation<sup>2-4<\/sup><\/li>\r\n \t<li>Helps babies return to normal weight &amp; growth patterns<sup>2-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Pleasant taste, unlike some extensively hydrolysed or amino-acid-based formulas<sup>2,3,7<\/sup><\/li>\r\n \t<li>Suitable to lactose-intolerant babies<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n \t<li>Contains Omega 3 (\u03b1-Linolenic acid) and 6 (Linoleic acid) from vegetable source<\/li>\r\n \t<li><strong>No prescription needed<\/strong> (Available only from pharmacy and online)<\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Allergy-Product-Information-and-Evidence.pdf\">Novalac Allergy Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/www.allergy.org.au\/hp\/papers\/guide-for-milk-substitutes-cows-milk-allergy\"><u>Australasian Society of Clinical Immunology and Allergy (ASCIA) Guide for Milk Substitutes in Cow\u2019s Milk Allergy\u00a0<\/u><\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/08\/Novalac-Allergy-NIP-AF-07488-2.pdf\">Novalac Allergy Nutritional Information Panel\u00a0<\/a><\/li>\r\n<\/ul>\r\n*Unless allergic to rice.\r\n\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Australasian Society of Clinical Immunology and Allergy (ASCIA), Guide for milk substitutes in cow\u2019s milk allergy, June 2023.<\/li>\r\n \t<li>Vandenplas Y et al. Eur J Paediatr. 2014; 173(9);1209-16<\/li>\r\n \t<li>Vandenplas Y et al. Arch Dis Child. 2014; 99:933-6<\/li>\r\n \t<li>Reche M et al. Patriatr Allergy Immunol. 2010; 21:577-85<\/li>\r\n \t<li>D\u2019Auria E et al. J Int Med Res. 2003; 31:215-22<\/li>\r\n \t<li>Agostoni C et al. Pediatr Allergy Immunol. 2007; 18:599-606<\/li>\r\n \t<li>Pedrosa M et al. J Investig Allergol Clin Immunol. 2006; 16:351-6<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-15-at-11.36.22-am.png","cat_name":"outofstock","slug":"outofstock","sku_code":null}],"medication-lubricant":[{"ID":"62829","post_title":"GLOUP\u00ae (Tube)","post_content":"<strong>Are you asking patients if they find tablets difficult to swallow?<\/strong><b>\r\n<\/b>Up to 40% of people face problems with the intake of oral medication*.\r\n\r\n<strong>Who is at risk of swallowing difficulties?<\/strong><b>\r\n<\/b>\u2022 People taking multiple medications\r\n\u2022 Anyone consuming large tablets (e.g. metformin)\r\n\u2022 People with a dry mouth caused by medication or illness\r\n\u2022 Children transitioning to tablets\r\n\u2022 Disability Patients\r\n\u2022 Stroke Patients\r\n\u2022 The elderly\r\n\r\n<strong>What are patients doing if they can\u2019t swallow tablets?<\/strong><b>\r\n<\/b>They may be non-compliant, or crush\/split tablets which can lead to an increased risk in side-effects, decreased therapeutic effect and loss of dose.\r\n\r\n<strong>Why use Gloup\u00ae?<\/strong><b>\r\n<\/b>\u2022 It's a slippery gel that makes tablets easier to swallow\r\n\u2022 Reduces the need to crush tablets*\r\n\u2022 Masks the bitter taste of tablets\r\n\u2022 Reduces the chance of tablets getting stuck*\r\n\u2022 No known interactions with medications\r\n\u2022 Minimal or no impact on absorption*\r\n\u2022 Clinical guidelines* recommend trying a medication lubricant for patients experiencing difficulty with medication intake\r\n\r\nGloup\u00ae is available in 5 flavours and 2 thicknesses\r\n\r\n<strong>Gloup\u00ae assisted with over 15 million medication administrations in Australia in 2023!<\/strong>\r\n\r\n*clinical evidence available upon request\r\n\r\n<a href=\"https:\/\/gloup.com.au\/for-hcps\/training-videos\/\">Click here to watch videos about Gloup<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Gloup-Family-A4-Patient-Info-Sheet.pdf\">Click here for a Patient Information Sheet<\/a>\r\n\r\n<strong>How to use Gloup\u00ae:<\/strong><img class=\"alignnone size-full wp-image-61267\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/How-to-use-Gloup-icons.png\" alt=\"\" width=\"2480\" height=\"1412\" \/>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Gloup-Family-150ml-Pack-Shot-Mockup-Facing-Right-No-Background.png","cat_name":"Medication lubricant","slug":"medication-lubricant","sku_code":null},{"ID":"62831","post_title":"GLOUP\u00ae (Pump Bottle)","post_content":"<strong>Are you asking patients if they find tablets difficult to swallow?<\/strong><b>\r\n<\/b>Up to 40% of people face problems with the intake of oral medication*.\r\n\r\n<strong>Who is at risk of swallowing difficulties?<\/strong><b>\r\n<\/b>\u2022 People taking multiple medications\r\n\u2022 Anyone consuming large tablets (e.g. metformin)\r\n\u2022 People with a dry mouth caused by medication or illness\r\n\u2022 Children transitioning to tablets\r\n\u2022 Disability Patients\r\n\u2022 Stroke Patients\r\n\u2022 The elderly\r\n\r\n<strong>What are patients doing if they can\u2019t swallow tablets?<\/strong><b>\r\n<\/b>They may be non-compliant, or crush\/split tablets which can lead to an increased risk in side-effects, decreased therapeutic effect and loss of dose.\r\n\r\n<strong>Why use Gloup\u00ae?<\/strong><b>\r\n<\/b>\u2022 It's a slippery gel that makes tablets easier to swallow\r\n\u2022 Reduces the need to crush tablets*\r\n\u2022 Masks the bitter taste of tablets\r\n\u2022 Reduces the chance of tablets getting stuck*\r\n\u2022 No known interactions with medications\r\n\u2022 Minimal or no impact on absorption*\r\n\u2022 Clinical guidelines* recommend trying a medication lubricant for patients experiencing difficulty with medication intake\r\n\r\nGloup\u00ae is available in 5 flavours and 2 thicknesses\r\n\r\n<strong>Gloup\u00ae assisted with over 15 million medication administrations in Australia in 2023!<\/strong>\r\n\r\n*clinical evidence available upon request\r\n\r\n<a href=\"https:\/\/gloup.com.au\/for-hcps\/training-videos\/\">Click here to watch videos about Gloup<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Gloup-Family-A4-Patient-Info-Sheet.pdf\">Click here for a Patient Information Sheet<\/a>\r\n\r\n<strong>How to use Gloup\u00ae:<\/strong><img class=\"alignnone size-full wp-image-61267\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/How-to-use-Gloup-icons.png\" alt=\"\" width=\"2480\" height=\"1412\" \/>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/09\/raspberry-bottle-box.jpg","cat_name":"Medication lubricant","slug":"medication-lubricant","sku_code":null}],"cold-flu":[{"ID":"63811","post_title":"MAXIGESIC\u00ae COLD & FLU HOT DRINK","post_content":"https:\/\/youtu.be\/hA3CTYqBn_E?feature=shared\r\n\r\n&nbsp;\r\n\r\nMaxigesic\u00ae Cold &amp; Flu Hot Drink provides temporary relief of headache pain, sinus pain, sore throat, aches and pains associated with colds &amp; flu, and also helps reduce fever. It also provides temporary relief of pain associated with migraine headache, tension headache, toothache, dental procedures, backache, arthritis, rheumatic pain, period pain, muscular pain, and tennis elbow.\r\n\r\nRegular Strength contains Paracetamol 500 mg + Ibuprofen 150 mg per sachet.\r\n\r\nAlways read the label and follow the directions for use. Incorrect use could be harmful.\r\n\r\nAFT\u00a0Pharmaceuticals Pty Ltd, Sydney. Patent No. 2005260243.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/12\/Maxigesic-CFHD-Angled-right-.png","cat_name":"Cold &amp; Flu","slug":"cold-flu","sku_code":null}],"info-urogestan":[{"ID":"31227","post_title":"UTROGESTAN\u00ae","post_content":"<p class=\"p1\">Luteal Phase Support<sup>1<\/sup><\/p>\r\n<p class=\"p1\">Utrogestan is indicated for use in luteal phase support during Assisted Reproductive Treatment (ART) cycles and is reimbursed for the first two weeks following embryo transfer<sup>2<\/sup>.<\/p>\r\n<p class=\"p1\">Utrogestan is available as 200mg soft vaginal capsules in packs of 42 capsules (two weeks supply).<\/p>\r\n<p class=\"p1\">Dosage is three times daily, administered vaginally, from the day of embryo transfer until at least the 7th week of pregnancy and no later than the 12th week of pregnancy.<\/p>\r\n<p class=\"p1\">Utrogestan (micronised progesterone) is TGA-approved for prevention of preterm birth, in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix \u226425 mm) and\/or a history of spontaneous preterm birth.<sup>1<\/sup> Compared to placebo, vaginal progesterone significantly reduces the risk of preterm birth and improves perinatal outcomes in women with singleton pregnancy and a short cervix, with proven maternal and neonatal tolerability.<sup>1, 3-5<\/sup> Utrogestan vaginal capsules are administered once-daily, are easy to insert and readily absorbed.<sup>1<\/sup><\/p>\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li class=\"p1\">Utrogestan<sup>\u00ae<\/sup> (micronised progesterone) Product Information, updated 13 November 2019.<\/li>\r\n \t<li>Pharmaceutical Benefits Scheme\u00a0Available at <a href=\"https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines\">https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines<\/a><\/li>\r\n \t<li class=\"p1\">Romero R et al. Am J Obstet Gynaecol 2018;218(2):161-80.<\/li>\r\n \t<li class=\"p1\">Norman JE et al. Lancet 2016;387:2106-16.<\/li>\r\n \t<li class=\"p1\">Fonseca EB et al. N Engl J Med 2007;357:462-9.<\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Utrogestan<sup>\u00ae<\/sup> is a registered trademark of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\n<p class=\"p1\">UTR0514<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Utrogestan-Packaging-Images_Utrogestan-Pack_Caps-1.jpg","cat_name":"I would like more information on Utrogestan","slug":"info-urogestan","sku_code":null}],"i-would-like-a-rep-visit-in-person-if-available-or-by-phone-mail-or-email-if-no-local-rep-available":[{"ID":"3697","post_title":"TESTOGEL\u00ae","post_content":"Testogel\u00ae\u00a0is indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.\r\n\r\n<a href=\"https:\/\/vimeo.com\/303199072\">Please click here to watch a video on Testogel\u00ae<\/a>\r\n\r\nTestogel restores and maintains testosterone levels in the normal range.\r\n\r\nIn men with hypogonadism, Testogel\u00ae can:\r\n<ul>\r\n \t<li>Improve mood<\/li>\r\n \t<li>Improve sexual function<\/li>\r\n \t<li>Improve body composition<\/li>\r\n \t<li>Increase muscle strength<\/li>\r\n \t<li>Strengthen bones<\/li>\r\n \t<li>Improve blood sugar, blood pressure and bad cholesterol<\/li>\r\n \t<li>Improve overall satisfaction with life<\/li>\r\n<\/ul>\r\nTestogel\u00ae is absorbed through the skin and then slowly moves into the blood stream.\r\n\r\nTestogel\u00ae is natural \u201cbody identical\u201d testosterone.\u00a0It mimics the normal daily rhythm of natural testosterone production with daily application.\r\n<div class=\"ref-sup-wrap\"><\/div>\r\n<img class=\"alignnone size-full wp-image-63028\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/06\/testogel-1.png\" alt=\"\" width=\"787\" height=\"633\" \/>","guid":"http:\/\/mysamples.benslater.me\/wp-content\/uploads\/2018\/06\/testogel.png","cat_name":"I would like a rep visit - in person if available, or by phone, mail or email if no local rep available","slug":"i-would-like-a-rep-visit-in-person-if-available-or-by-phone-mail-or-email-if-no-local-rep-available","sku_code":null}],"i-would-like-to-request-patient-support-materials-for-this-product":[{"ID":"3697","post_title":"TESTOGEL\u00ae","post_content":"Testogel\u00ae\u00a0is indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.\r\n\r\n<a href=\"https:\/\/vimeo.com\/303199072\">Please click here to watch a video on Testogel\u00ae<\/a>\r\n\r\nTestogel restores and maintains testosterone levels in the normal range.\r\n\r\nIn men with hypogonadism, Testogel\u00ae can:\r\n<ul>\r\n \t<li>Improve mood<\/li>\r\n \t<li>Improve sexual function<\/li>\r\n \t<li>Improve body composition<\/li>\r\n \t<li>Increase muscle strength<\/li>\r\n \t<li>Strengthen bones<\/li>\r\n \t<li>Improve blood sugar, blood pressure and bad cholesterol<\/li>\r\n \t<li>Improve overall satisfaction with life<\/li>\r\n<\/ul>\r\nTestogel\u00ae is absorbed through the skin and then slowly moves into the blood stream.\r\n\r\nTestogel\u00ae is natural \u201cbody identical\u201d testosterone.\u00a0It mimics the normal daily rhythm of natural testosterone production with daily application.\r\n<div class=\"ref-sup-wrap\"><\/div>\r\n<img class=\"alignnone size-full wp-image-63028\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/06\/testogel-1.png\" alt=\"\" width=\"787\" height=\"633\" \/>","guid":"http:\/\/mysamples.benslater.me\/wp-content\/uploads\/2018\/06\/testogel.png","cat_name":"I would like to request patient support materials for this product","slug":"i-would-like-to-request-patient-support-materials-for-this-product","sku_code":null},{"ID":"38472","post_title":"ABSTRAL (Fentanyl citrate)","post_content":"<p class=\"p1\">Breakthrough cancer pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.<\/p>\r\n[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/05\/ABS-AU-1404-How-to-Take-Abstral-patient-video-2.mp4\"][\/video]\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK ABOVE<\/strong><\/span>\u00a0to view \"How to take\" video\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK HERE<\/strong><\/span> to visit the Abstral website\r\n<p class=\"p1\">ABSTRAL should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain.<\/p>\r\n<p class=\"p1\">Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily or an equivalent analgesic dose of another opioid for a week or longer.<\/p>\r\n<p class=\"p1\">ABSTRAL sublingual tablets should be administered directly under the tongue at the deepest part. ABSTRAL sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.<\/p>\r\nSublingual Abstral dissolves quickly and is absorbed through the sublingual\u00a0mucosa to provide rapid\u00a0analgesia. <sup id=\"cite_ref-trib_33-0\" class=\"reference\"><\/sup>Fentanyl is a highly lipophilic compound,<sup id=\"cite_ref-trib_33-1\" class=\"reference\"><\/sup><sup id=\"cite_ref-34\" class=\"reference\"><\/sup> which is well absorbed sublingually and generally well tolerated.\u00a0<sup id=\"cite_ref-trib_33-2\" class=\"reference\"><\/sup>Such forms are particularly useful for breakthrough cancer pain episodes, which are often rapid in onset, short in duration and severe in intensity.<sup id=\"cite_ref-35\" class=\"reference\"><\/sup>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=47145\" rel=\"attachment wp-att-47145\"><img class=\"wp-image-47145 aligncenter\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/01\/Screen-Shot-2022-04-07-at-3.32.02-pm.png\" alt=\"\" width=\"300\" height=\"94\" \/><\/a>\r\n\r\nA.Menarini Pty Ltd. Level 8, 67 Albert Avenue, Chatswood NSW 2067. Tel: 1800 644 542.ABN 62 116 935 758. <span class=\"il\">ABS<\/span>-AU-<span class=\"gmail_default\">1747<\/span> June 2022.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/04\/Abstral_logos_Red-Only.jpg","cat_name":"I would like to request patient support materials for this product","slug":"i-would-like-to-request-patient-support-materials-for-this-product","sku_code":null}],"i-would-like-a-rep-visit-or-more-information-about-this-product":[{"ID":"3957","post_title":"MAXIGESIC","post_content":"Developed in New Zealand, Maxigesic\u00ae is a unique, patented combination of paracetamol 500mg and ibuprofen 150mg that provides fast, effective double action relief for a wide range of pain symptoms, and also reduces inflammation and fever.\r\n\r\nAt maximum dosage, Maxigesic\u00ae is clinically proven to provide better, faster pain relief than paracetamol or ibuprofen alone<sup>1<\/sup>:\r\n<ul>\r\n \t<li>78% more effective relief than paracetamol alone<sup>1<\/sup><\/li>\r\n \t<li>36% more effective relief than ibuprofen alone<sup>1<\/sup><\/li>\r\n \t<li>Faster meaningful pain relief than paracetamol or ibuprofen alone<sup>1<\/sup><\/li>\r\n<\/ul>\r\nMaxigesic\u00ae also provides significantly more effective pain relief than paracetamol or ibuprofen alone within the first dosing period (6 hours)<sup>1<\/sup>, and is the only combination analgesic that provides the maximum recommended daily OTC dose of paracetamol 4000mg and ibuprofen 1200mg, if required (2 tablets, four times per day).\r\n\r\nMaxigesic\u00ae is also a well-tolerated combination for patients, with no more adverse events than paracetamol or ibuprofen alone<sup>2<\/sup>.\r\n\r\nMaxigesic\u00ae is indicated for the temporary relief of pain and reduction of fever and the discomfort associated with fever. It is suitable for the temporary relief of pain associated with headache, migraine headache, tension headache, toothache, dental procedures, backache, arthritis, rheumatic pain, period pain, muscular pain, tennis elbow, sinus pain, sore throat, and aches and pains associated with colds and flu.\r\n\r\nMaxigesic\u00ae is an unfunded medicine - available from pharmacies (10, 20, 50 and 100 tablets) and supermarkets (10 and 20 tablets).\r\n\r\n<em>Contraindications:<\/em> Hypersensitivity to any ingredient. Existing peptic ulceration or other stomach disorders, asthma, impaired kidney function or heart failure. Urticaria or rhinitis associated with aspirin or other NSAID\u2019s. Pregnancy except on doctor\u2019s advice. Do not use in the last trimester of pregnancy. Do not use in children under 12 years.\r\n\r\n<em>Precautions: <\/em>Do not combine with any other paracetamol or ibuprofen containing medications. Asthma, stomach ulcer, kidney disease, liver disease, heart failure, high blood pressure.\r\n\r\n<em>Adverse Effects:<\/em> Nausea, dyspepsia, rash, constipation, dizziness, oedema, tinnitis, headache, gastrointestinal bleeding (rare at OTC dose). Hepatic dysfunction and papillary necrosis may occur.\r\n\r\n<em>Interactions:<\/em> Anticoagulant medication, diuretics, lithium, methotrexate, or other medicines for pain relief.\r\n\r\n<em>Directions for use: <\/em>\r\n\r\nAdults and children over 12 years: Take 1 or 2 tablets every 4-6 hours, as required, up to a maximum of 8 tablets in 24 hours. Not recommended for children under 12 years of age.\r\n\r\n&nbsp;\r\n\r\nClick here to access the <a href=\"https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/m\/maxigesictab.pdf\">Maxigesic datasheet<\/a>\r\n\r\nClick here to visit the <a href=\"https:\/\/maxigesic.co.nz\/\">Maxigesic\u00ae website<\/a>\r\n\r\nClick here to view the Maxigesic\u00ae detail aid\r\n\r\nClick here to view Maxigesic\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/748yPa7vRTs\">Brand<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/txSmp6USzdc\">Back Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/GgVHJH5zb-I\">Headache<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/qoguNnEWhg8\">Joint Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/W_coLBBWHU0\">Period Pain #1<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/aB4DBvMiDF0\">Period Pain #2<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Daniels et al (2018). Result achieved in a trial of post-operative pain relief after removal of at least 2 wisdom teeth using MAXIGESIC\u00ae (Paracetamol 975mg\/Ibuprofen 292.5mg) compared with Paracetamol 975mg or Ibuprofen 292.5mg alone 4 times a day (Paracetamol 3900mg or Ibuprofen 1170mg per day). Study results assessed on the intent-to-treat (ITT) population with adjustment for the use of rescue medication. MAXIGESIC\u00ae 975\/292.5mg US combination is bioequivalent to MAXIGESIC\u00ae 1000\/300mg NZ combination at full dose (Aitken et al, 2018). Research sponsored by AFT Pharmaceuticals. 2. Aitken P, Stanescu I, Playne R, Zhang J, Frampton C and Atkinson HC (2019). \u201cAn Integrated Safety Analysis of Combined Acetaminophen and ibuprofen (MAXIGESIC\u00ae\/Combogesic\u00ae) in Adults\u201d, Journal of Pain Research 2019:12 621-634.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\nAFT Pharmaceuticals Ltd, Auckland\r\n\r\n<strong><em>Freephone:<\/em><\/strong> \u00a0\u00a0\u00a0 0800 423 823\r\n\r\n<strong><em>Freefax:<\/em><\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0800 423 874\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-9.55.50-PM.png","cat_name":"I would like a Rep visit or more information about this product.","slug":"i-would-like-a-rep-visit-or-more-information-about-this-product","sku_code":null},{"ID":"3692","post_title":"CRYSTADERM","post_content":"Crystaderm\u00ae (Hydrogen Peroxide cream 1% w\/w, 10g and 15g) is a first aid antiseptic cream for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, burns and school sores (impetigo).\r\n\r\nCrystaderm\u00ae is a broad-spectrum, preservative-free antiseptic cream that slowly releases hydrogen peroxide from lipid crystals for effective protection against skin infection with no known bacterial resistance<sup>1<\/sup> unlike topical antibiotics. Hydrogen peroxide is a potent agent against many types of bacteria, some fungi, and viruses, that acts by destroying essential components of the cells of these organisms.\r\n\r\nCrystaderm\u00ae dries fast and adheres to both moist and dry areas, and doesn\u2019t stain skin, hands and fabric. A small amount of Crystaderm\u00ae goes a long way so can be applied sparingly, and the smooth, pearly white cream vanishes quickly on application.\r\n\r\nCrystaderm\u00ae 10g cream is a fully funded general sales medicine - available from pharmacies and supermarkets. Crystaderm\u00ae 15g is an unfunded medicine.\r\n\r\n<em>Contraindications:<\/em> Known hypersensitivity to any ingredient.\r\n\r\n<em>Precautions: <\/em>Use under medical guidance in pregnancy and breastfeeding. Avoid contact with the eyes. Do not use in the presence of iodine, permanganate and any other strong oxidising agents.\r\n\r\n<em>Adverse Effects:<\/em> Mild sensation of burning may be experienced for a short time after application.\r\n\r\n<em>Directions for use: <\/em>After cleansing the area, apply cream 2-3 times daily on affected area. A dry film will appear on the skin after application, which can be washed off with water.\r\n\r\n&nbsp;\r\n\r\nClick here to visit the <a href=\"https:\/\/crystaderm.co.nz\/\">Crystaderm website<\/a>\r\n\r\nClick here to view the Crystaderm\u00ae detail aid\r\n\r\nClick here to view Crystaderm\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/oNg9uWKfm2k\">First Aid video<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/tGINSugNu5I\">Acne video<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy for Treating Chronic Wounds, 2009, 49:1541\u20131549.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-10.00.13-PM.png","cat_name":"I would like a Rep visit or more information about this product.","slug":"i-would-like-a-rep-visit-or-more-information-about-this-product","sku_code":null}],"patient-info-utrogestan":[{"ID":"31227","post_title":"UTROGESTAN\u00ae","post_content":"<p class=\"p1\">Luteal Phase Support<sup>1<\/sup><\/p>\r\n<p class=\"p1\">Utrogestan is indicated for use in luteal phase support during Assisted Reproductive Treatment (ART) cycles and is reimbursed for the first two weeks following embryo transfer<sup>2<\/sup>.<\/p>\r\n<p class=\"p1\">Utrogestan is available as 200mg soft vaginal capsules in packs of 42 capsules (two weeks supply).<\/p>\r\n<p class=\"p1\">Dosage is three times daily, administered vaginally, from the day of embryo transfer until at least the 7th week of pregnancy and no later than the 12th week of pregnancy.<\/p>\r\n<p class=\"p1\">Utrogestan (micronised progesterone) is TGA-approved for prevention of preterm birth, in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix \u226425 mm) and\/or a history of spontaneous preterm birth.<sup>1<\/sup> Compared to placebo, vaginal progesterone significantly reduces the risk of preterm birth and improves perinatal outcomes in women with singleton pregnancy and a short cervix, with proven maternal and neonatal tolerability.<sup>1, 3-5<\/sup> Utrogestan vaginal capsules are administered once-daily, are easy to insert and readily absorbed.<sup>1<\/sup><\/p>\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li class=\"p1\">Utrogestan<sup>\u00ae<\/sup> (micronised progesterone) Product Information, updated 13 November 2019.<\/li>\r\n \t<li>Pharmaceutical Benefits Scheme\u00a0Available at <a href=\"https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines\">https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines<\/a><\/li>\r\n \t<li class=\"p1\">Romero R et al. Am J Obstet Gynaecol 2018;218(2):161-80.<\/li>\r\n \t<li class=\"p1\">Norman JE et al. Lancet 2016;387:2106-16.<\/li>\r\n \t<li class=\"p1\">Fonseca EB et al. N Engl J Med 2007;357:462-9.<\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Utrogestan<sup>\u00ae<\/sup> is a registered trademark of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\n<p class=\"p1\">UTR0514<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Utrogestan-Packaging-Images_Utrogestan-Pack_Caps-1.jpg","cat_name":"I would like patient information on Utrogestan","slug":"patient-info-utrogestan","sku_code":null}],"i-am-a-pharmacist-and-would-like-to-be-sent-a-deal-to-purchase-this-product":[{"ID":"3692","post_title":"CRYSTADERM","post_content":"Crystaderm\u00ae (Hydrogen Peroxide cream 1% w\/w, 10g and 15g) is a first aid antiseptic cream for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, burns and school sores (impetigo).\r\n\r\nCrystaderm\u00ae is a broad-spectrum, preservative-free antiseptic cream that slowly releases hydrogen peroxide from lipid crystals for effective protection against skin infection with no known bacterial resistance<sup>1<\/sup> unlike topical antibiotics. Hydrogen peroxide is a potent agent against many types of bacteria, some fungi, and viruses, that acts by destroying essential components of the cells of these organisms.\r\n\r\nCrystaderm\u00ae dries fast and adheres to both moist and dry areas, and doesn\u2019t stain skin, hands and fabric. A small amount of Crystaderm\u00ae goes a long way so can be applied sparingly, and the smooth, pearly white cream vanishes quickly on application.\r\n\r\nCrystaderm\u00ae 10g cream is a fully funded general sales medicine - available from pharmacies and supermarkets. Crystaderm\u00ae 15g is an unfunded medicine.\r\n\r\n<em>Contraindications:<\/em> Known hypersensitivity to any ingredient.\r\n\r\n<em>Precautions: <\/em>Use under medical guidance in pregnancy and breastfeeding. Avoid contact with the eyes. Do not use in the presence of iodine, permanganate and any other strong oxidising agents.\r\n\r\n<em>Adverse Effects:<\/em> Mild sensation of burning may be experienced for a short time after application.\r\n\r\n<em>Directions for use: <\/em>After cleansing the area, apply cream 2-3 times daily on affected area. A dry film will appear on the skin after application, which can be washed off with water.\r\n\r\n&nbsp;\r\n\r\nClick here to visit the <a href=\"https:\/\/crystaderm.co.nz\/\">Crystaderm website<\/a>\r\n\r\nClick here to view the Crystaderm\u00ae detail aid\r\n\r\nClick here to view Crystaderm\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/oNg9uWKfm2k\">First Aid video<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/tGINSugNu5I\">Acne video<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy for Treating Chronic Wounds, 2009, 49:1541\u20131549.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-10.00.13-PM.png","cat_name":"I am a Pharmacist and would like to be sent a deal to purchase this product.","slug":"i-am-a-pharmacist-and-would-like-to-be-sent-a-deal-to-purchase-this-product","sku_code":null}],"variable":[{"ID":"3692","post_title":"CRYSTADERM","post_content":"Crystaderm\u00ae (Hydrogen Peroxide cream 1% w\/w, 10g and 15g) is a first aid antiseptic cream for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, burns and school sores (impetigo).\r\n\r\nCrystaderm\u00ae is a broad-spectrum, preservative-free antiseptic cream that slowly releases hydrogen peroxide from lipid crystals for effective protection against skin infection with no known bacterial resistance<sup>1<\/sup> unlike topical antibiotics. Hydrogen peroxide is a potent agent against many types of bacteria, some fungi, and viruses, that acts by destroying essential components of the cells of these organisms.\r\n\r\nCrystaderm\u00ae dries fast and adheres to both moist and dry areas, and doesn\u2019t stain skin, hands and fabric. A small amount of Crystaderm\u00ae goes a long way so can be applied sparingly, and the smooth, pearly white cream vanishes quickly on application.\r\n\r\nCrystaderm\u00ae 10g cream is a fully funded general sales medicine - available from pharmacies and supermarkets. Crystaderm\u00ae 15g is an unfunded medicine.\r\n\r\n<em>Contraindications:<\/em> Known hypersensitivity to any ingredient.\r\n\r\n<em>Precautions: <\/em>Use under medical guidance in pregnancy and breastfeeding. Avoid contact with the eyes. Do not use in the presence of iodine, permanganate and any other strong oxidising agents.\r\n\r\n<em>Adverse Effects:<\/em> Mild sensation of burning may be experienced for a short time after application.\r\n\r\n<em>Directions for use: <\/em>After cleansing the area, apply cream 2-3 times daily on affected area. A dry film will appear on the skin after application, which can be washed off with water.\r\n\r\n&nbsp;\r\n\r\nClick here to visit the <a href=\"https:\/\/crystaderm.co.nz\/\">Crystaderm website<\/a>\r\n\r\nClick here to view the Crystaderm\u00ae detail aid\r\n\r\nClick here to view Crystaderm\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/oNg9uWKfm2k\">First Aid video<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/tGINSugNu5I\">Acne video<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy for Treating Chronic Wounds, 2009, 49:1541\u20131549.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-10.00.13-PM.png","cat_name":"variable","slug":"variable","sku_code":null},{"ID":"43063","post_title":"DIPHERELINE\u00ae (triptorelin embonate) 22.5mg Paediatric Product Familiarisation Program (PFP)","post_content":"The Diphereline<sup>\u00ae<\/sup> 22.5mg PFP for CPP provides healthcare professionals the opportunity to familiarise themselves with, and gain experience using, Diphereline<sup>\u00ae<\/sup> 22.5mg.\r\n\r\nFor eligible patients who may benefit from Australia\u2019s first and only six-month GnRHa CPP treatment<sup>1<\/sup>, the PFP provides access to Diphereline<sup>\u00ae<\/sup> at no charge. The program will remain available until 31 March 2022 or until Diphereline<sup>\u00ae<\/sup> 22.5mg is listed on the PBS, whichever occurs first*.\r\n\r\nPBS information: Diphereline<sup>\u00ae<\/sup> 22.5mg for Central Precocious Puberty is not listed on the Pharmaceutical Benefits Scheme (PBS).\r\n\r\nPlease ensure that enrolled patients\/carers understand the Program and document their consent to the terms of the PFP. Should you have any questions, please do not hesitate to contact Ipsen.\r\n\r\n<em>*If Diphereline<sup>\u00ae<\/sup> is not listed on the PBS on 1 April 2022, or if participants are ineligible to receive Diphereline<sup>\u00ae<\/sup> treatment via the PBS, Ipsen reserves the right to revise ongoing supply. In this instance, Diphereline<sup>\u00ae<\/sup> may only be available with a private prescription.<\/em>\r\n\r\n&nbsp;\r\n\r\n<strong>Eligibility Criteria <\/strong>\r\n\r\nPatients eligible for the Paediatric Diphereline<sup>\u00ae<\/sup> (triptorelin embonate) 22.5mg PFP are:\r\n<ul>\r\n \t<li>Girls with a documented diagnosis of CPP with a date of onset of &lt; 8 years of age and who will not be older than 9 years and 3 months on 1 August 2021 when commencing treatment<\/li>\r\n \t<li>Boys with a documented diagnosis of CPP with a date of onset of &lt; 9 years of age and who will not be older than 10 years and 3 months on 1 August 2021 when commencing treatment<\/li>\r\n \t<li>Na\u00efve to any prior therapies for CPP<\/li>\r\n<\/ul>\r\n&nbsp;\r\n\r\nThese criteria have been put in place specifically to allow all patients participating in the program the opportunity to use an alternative GnRHa should Diphereline<sup>\u00ae<\/sup> 22.5mg (triptorelin embonate) not be PBS-listed by 1 April 2022.\r\n\r\n&nbsp;\r\n\r\nOne Diphereline<sup>\u00ae<\/sup> 22.5mg PFP Welcome pack contains:\r\n<ul>\r\n \t<li>One vial of Diphereline 22.5mg (6-month formulation) for reconstitution<\/li>\r\n \t<li>Diphereline Product Information<\/li>\r\n \t<li>Diphereline Consumer Medicines Information<\/li>\r\n \t<li>The Diphereline 22.5mg reconstitution leaflet<\/li>\r\n<\/ul>\r\nThe pack(s) will be shipped to the address you registered within 24-48 hours of the order being placed.\r\n\r\n&nbsp;\r\n\r\nLink to the PI &amp; CMI: <a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=&amp;q=Diphereline&amp;r=\/\">TGA eBS - Product and Consumer Medicine Information<\/a>\r\n\r\n&nbsp;\r\n\r\nBefore prescribing please refer to full Product Information\r\n\r\nwhich is available from Ipsen Medical Information.\r\n\r\nPh: 1800 317 033 or from\r\n\r\n<a href=\"http:\/\/www.guildlink.com.au\/gc\/ws\/ipsen\/pi.cfm?product=ispdi\">www.guildlink.com.au\/gc\/ws\/ipsen\/pi.cfm?product=ispdi<\/a>\r\n<p class=\"p1\">\u25bc This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <a href=\"http:\/\/www.tga.gov.au\/reporting-problems\">www.tga.gov.au\/reporting-problems<\/a>.<\/p>\r\n&nbsp;\r\n\r\n<strong>Diphereline\u00ae: <\/strong>Triptorelin embonate 22.5 mg (6-month formulation). <strong>Indications: <\/strong>Treatment of children 2 years and older with central precocious puberty. <strong>Dose: <\/strong>22.5 mg triptorelin (1 vial) once every six months. <strong>Administration: <\/strong>Single intramuscular injection; 1 vial reconstituted using 2 mL sterile water for injection; injection site should be varied periodically; inadvertent intravascular injection must be strictly avoided (see full PI). <strong>Contraindications: <\/strong>Known hypersensitivity to triptorelin or product excipients, GnRH or other GnRH agonist analogues; pregnancy and lactation. <strong>Precautions:<\/strong> Children with progressive brain tumours; pseudo-precocious puberty and gonadotropin-independent precocious puberty; mild to moderate vaginal bleeding in first month (girls); decreased bone mineral density during treatment (bone mass accrual preserved after treatment cessation); slipped capital femoral epiphysis after withdrawal of treatment; depression and mood changes; pituitary apoplexy (see full PI). <strong>Drug Interactions: <\/strong>Caution with intramuscular injection in patients treated with anticoagulants; caution when administered with other medicines affecting pituitary secretion of gonadotrophins; hyperprolactinaemic agents should not be prescribed concomitantly. <strong>Adverse Events: <\/strong>Very common: Vaginal bleeding (including vaginal haemorrhage, withdrawal bleed, uterine haemorrhage, vaginal discharge, bleeding and spotting). Common: abdominal pain, injection site reaction, hypersensitivity, increased weight, headache, acne, hot flushes (see full PI). <strong>Storage: <\/strong>Store below 25\u00b0C.\r\n\r\n&nbsp;\r\n\r\nIPSEN Pty Ltd. (ABN 47 095 036 909]). Telephone: +61 (3) 8544 8100. Facsimile: +61 (3) 9562 5152. Brandon Office Park, Level 2, Building 4, 540 Springvale Road, Glen Waverley 3150, Victoria, Australia. TRI-AU-000584. Date prepared: September 2021.\r\n\r\n<u>\u00a0<\/u>\r\n\r\n<u>Reference<\/u>\r\n<ol>\r\n \t<li>Therapeutic Goods Administration, Diphereline<sup>\u00ae<\/sup>. Available at: <a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=PI&amp;q=Diphereline%20\">https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=PI&amp;q=Diphereline%20<\/a>. Last accessed September 2021.<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/08\/Diphereline_Packshot_V2.jpg","cat_name":"variable","slug":"variable","sku_code":null}],"hcp_material":[{"ID":"38472","post_title":"ABSTRAL (Fentanyl citrate)","post_content":"<p class=\"p1\">Breakthrough cancer pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.<\/p>\r\n[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/05\/ABS-AU-1404-How-to-Take-Abstral-patient-video-2.mp4\"][\/video]\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK ABOVE<\/strong><\/span>\u00a0to view \"How to take\" video\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK HERE<\/strong><\/span> to visit the Abstral website\r\n<p class=\"p1\">ABSTRAL should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain.<\/p>\r\n<p class=\"p1\">Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily or an equivalent analgesic dose of another opioid for a week or longer.<\/p>\r\n<p class=\"p1\">ABSTRAL sublingual tablets should be administered directly under the tongue at the deepest part. ABSTRAL sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.<\/p>\r\nSublingual Abstral dissolves quickly and is absorbed through the sublingual\u00a0mucosa to provide rapid\u00a0analgesia. <sup id=\"cite_ref-trib_33-0\" class=\"reference\"><\/sup>Fentanyl is a highly lipophilic compound,<sup id=\"cite_ref-trib_33-1\" class=\"reference\"><\/sup><sup id=\"cite_ref-34\" class=\"reference\"><\/sup> which is well absorbed sublingually and generally well tolerated.\u00a0<sup id=\"cite_ref-trib_33-2\" class=\"reference\"><\/sup>Such forms are particularly useful for breakthrough cancer pain episodes, which are often rapid in onset, short in duration and severe in intensity.<sup id=\"cite_ref-35\" class=\"reference\"><\/sup>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=47145\" rel=\"attachment wp-att-47145\"><img class=\"wp-image-47145 aligncenter\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/01\/Screen-Shot-2022-04-07-at-3.32.02-pm.png\" alt=\"\" width=\"300\" height=\"94\" \/><\/a>\r\n\r\nA.Menarini Pty Ltd. Level 8, 67 Albert Avenue, Chatswood NSW 2067. Tel: 1800 644 542.ABN 62 116 935 758. <span class=\"il\">ABS<\/span>-AU-<span class=\"gmail_default\">1747<\/span> June 2022.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/04\/Abstral_logos_Red-Only.jpg","cat_name":"I would like to request Healthcare Professional material","slug":"hcp_material","sku_code":null}],"communications-ipsen":[{"ID":"43063","post_title":"DIPHERELINE\u00ae (triptorelin embonate) 22.5mg Paediatric Product Familiarisation Program (PFP)","post_content":"The Diphereline<sup>\u00ae<\/sup> 22.5mg PFP for CPP provides healthcare professionals the opportunity to familiarise themselves with, and gain experience using, Diphereline<sup>\u00ae<\/sup> 22.5mg.\r\n\r\nFor eligible patients who may benefit from Australia\u2019s first and only six-month GnRHa CPP treatment<sup>1<\/sup>, the PFP provides access to Diphereline<sup>\u00ae<\/sup> at no charge. The program will remain available until 31 March 2022 or until Diphereline<sup>\u00ae<\/sup> 22.5mg is listed on the PBS, whichever occurs first*.\r\n\r\nPBS information: Diphereline<sup>\u00ae<\/sup> 22.5mg for Central Precocious Puberty is not listed on the Pharmaceutical Benefits Scheme (PBS).\r\n\r\nPlease ensure that enrolled patients\/carers understand the Program and document their consent to the terms of the PFP. Should you have any questions, please do not hesitate to contact Ipsen.\r\n\r\n<em>*If Diphereline<sup>\u00ae<\/sup> is not listed on the PBS on 1 April 2022, or if participants are ineligible to receive Diphereline<sup>\u00ae<\/sup> treatment via the PBS, Ipsen reserves the right to revise ongoing supply. In this instance, Diphereline<sup>\u00ae<\/sup> may only be available with a private prescription.<\/em>\r\n\r\n&nbsp;\r\n\r\n<strong>Eligibility Criteria <\/strong>\r\n\r\nPatients eligible for the Paediatric Diphereline<sup>\u00ae<\/sup> (triptorelin embonate) 22.5mg PFP are:\r\n<ul>\r\n \t<li>Girls with a documented diagnosis of CPP with a date of onset of &lt; 8 years of age and who will not be older than 9 years and 3 months on 1 August 2021 when commencing treatment<\/li>\r\n \t<li>Boys with a documented diagnosis of CPP with a date of onset of &lt; 9 years of age and who will not be older than 10 years and 3 months on 1 August 2021 when commencing treatment<\/li>\r\n \t<li>Na\u00efve to any prior therapies for CPP<\/li>\r\n<\/ul>\r\n&nbsp;\r\n\r\nThese criteria have been put in place specifically to allow all patients participating in the program the opportunity to use an alternative GnRHa should Diphereline<sup>\u00ae<\/sup> 22.5mg (triptorelin embonate) not be PBS-listed by 1 April 2022.\r\n\r\n&nbsp;\r\n\r\nOne Diphereline<sup>\u00ae<\/sup> 22.5mg PFP Welcome pack contains:\r\n<ul>\r\n \t<li>One vial of Diphereline 22.5mg (6-month formulation) for reconstitution<\/li>\r\n \t<li>Diphereline Product Information<\/li>\r\n \t<li>Diphereline Consumer Medicines Information<\/li>\r\n \t<li>The Diphereline 22.5mg reconstitution leaflet<\/li>\r\n<\/ul>\r\nThe pack(s) will be shipped to the address you registered within 24-48 hours of the order being placed.\r\n\r\n&nbsp;\r\n\r\nLink to the PI &amp; CMI: <a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=&amp;q=Diphereline&amp;r=\/\">TGA eBS - Product and Consumer Medicine Information<\/a>\r\n\r\n&nbsp;\r\n\r\nBefore prescribing please refer to full Product Information\r\n\r\nwhich is available from Ipsen Medical Information.\r\n\r\nPh: 1800 317 033 or from\r\n\r\n<a href=\"http:\/\/www.guildlink.com.au\/gc\/ws\/ipsen\/pi.cfm?product=ispdi\">www.guildlink.com.au\/gc\/ws\/ipsen\/pi.cfm?product=ispdi<\/a>\r\n<p class=\"p1\">\u25bc This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <a href=\"http:\/\/www.tga.gov.au\/reporting-problems\">www.tga.gov.au\/reporting-problems<\/a>.<\/p>\r\n&nbsp;\r\n\r\n<strong>Diphereline\u00ae: <\/strong>Triptorelin embonate 22.5 mg (6-month formulation). <strong>Indications: <\/strong>Treatment of children 2 years and older with central precocious puberty. <strong>Dose: <\/strong>22.5 mg triptorelin (1 vial) once every six months. <strong>Administration: <\/strong>Single intramuscular injection; 1 vial reconstituted using 2 mL sterile water for injection; injection site should be varied periodically; inadvertent intravascular injection must be strictly avoided (see full PI). <strong>Contraindications: <\/strong>Known hypersensitivity to triptorelin or product excipients, GnRH or other GnRH agonist analogues; pregnancy and lactation. <strong>Precautions:<\/strong> Children with progressive brain tumours; pseudo-precocious puberty and gonadotropin-independent precocious puberty; mild to moderate vaginal bleeding in first month (girls); decreased bone mineral density during treatment (bone mass accrual preserved after treatment cessation); slipped capital femoral epiphysis after withdrawal of treatment; depression and mood changes; pituitary apoplexy (see full PI). <strong>Drug Interactions: <\/strong>Caution with intramuscular injection in patients treated with anticoagulants; caution when administered with other medicines affecting pituitary secretion of gonadotrophins; hyperprolactinaemic agents should not be prescribed concomitantly. <strong>Adverse Events: <\/strong>Very common: Vaginal bleeding (including vaginal haemorrhage, withdrawal bleed, uterine haemorrhage, vaginal discharge, bleeding and spotting). Common: abdominal pain, injection site reaction, hypersensitivity, increased weight, headache, acne, hot flushes (see full PI). <strong>Storage: <\/strong>Store below 25\u00b0C.\r\n\r\n&nbsp;\r\n\r\nIPSEN Pty Ltd. (ABN 47 095 036 909]). Telephone: +61 (3) 8544 8100. Facsimile: +61 (3) 9562 5152. Brandon Office Park, Level 2, Building 4, 540 Springvale Road, Glen Waverley 3150, Victoria, Australia. TRI-AU-000584. Date prepared: September 2021.\r\n\r\n<u>\u00a0<\/u>\r\n\r\n<u>Reference<\/u>\r\n<ol>\r\n \t<li>Therapeutic Goods Administration, Diphereline<sup>\u00ae<\/sup>. Available at: <a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=PI&amp;q=Diphereline%20\">https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=PI&amp;q=Diphereline%20<\/a>. Last accessed September 2021.<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/08\/Diphereline_Packshot_V2.jpg","cat_name":"I agree to receive communications from Ipsen (optional)","slug":"communications-ipsen","sku_code":null}],"i-would-like-to-request-diphereline-preparation-and-administration-training-for-me-or-my-staff":[{"ID":"38635","post_title":"Diphereline<sup>&reg;<\/sup> (triptorelin embonate) 3.75mg (1 month formulation) Starter Pack Program","post_content":"<ul>\r\n \t<li>Before prescribing, please refer to full Product Information which is available from Ipsen Medical Information Ph: 1800 317 033 or from <u><a href=\"https:\/\/rss.medsinfo.com.au\/is\/pi.cfm?product=ispdi\">https:\/\/rss.medsinfo.com.au\/is\/pi.cfm?product=ispdi<\/a><\/u><\/li>\r\n \t<li>The Consumer Medical Information is available from <a href=\"https:\/\/rss.medsinfo.com.au\/is\/cmi.cfm?product=isccabot\">https:\/\/rss.medsinfo.com.au\/is\/cmi.cfm?product=isccabot<\/a><\/li>\r\n \t<li>This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse events at <u><a href=\"http:\/\/www.tga.gov.au\/reporting-problems\">www.tga.gov.au\/reporting-problems<\/a><\/u><\/li>\r\n \t<li>Diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.<\/li>\r\n \t<li>Diphereline 22.5 mg 6 month formulation only: Diphereline 22.5 mg is indicated for the treatment of children 2 years and older with central precocious puberty (CPP).<\/li>\r\n<\/ul>\r\nDiphereline\u00ae is a registered trademark. For further information about Diphereline\u00ae, contact Ipsen Pty Ltd, Level 5, 627 Chapel Street, South Yarra, VIC 3141, Australia.\r\n\r\nT: 1800 317 033 | E: info@ipsen.com.au | ABN 47 095 036 909.\r\n\r\nDate of preparation: XXXXXX . APPROVAL CODE: TRI-AU-000XXX","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/03\/dip.png","cat_name":"I would like to request Diphereline&reg; preparation and administration training for me or my staff","slug":"i-would-like-to-request-diphereline-preparation-and-administration-training-for-me-or-my-staff","sku_code":null}],"abstral-training":[{"ID":"38472","post_title":"ABSTRAL (Fentanyl citrate)","post_content":"<p class=\"p1\">Breakthrough cancer pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.<\/p>\r\n[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/05\/ABS-AU-1404-How-to-Take-Abstral-patient-video-2.mp4\"][\/video]\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK ABOVE<\/strong><\/span>\u00a0to view \"How to take\" video\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK HERE<\/strong><\/span> to visit the Abstral website\r\n<p class=\"p1\">ABSTRAL should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain.<\/p>\r\n<p class=\"p1\">Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily or an equivalent analgesic dose of another opioid for a week or longer.<\/p>\r\n<p class=\"p1\">ABSTRAL sublingual tablets should be administered directly under the tongue at the deepest part. ABSTRAL sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.<\/p>\r\nSublingual Abstral dissolves quickly and is absorbed through the sublingual\u00a0mucosa to provide rapid\u00a0analgesia. <sup id=\"cite_ref-trib_33-0\" class=\"reference\"><\/sup>Fentanyl is a highly lipophilic compound,<sup id=\"cite_ref-trib_33-1\" class=\"reference\"><\/sup><sup id=\"cite_ref-34\" class=\"reference\"><\/sup> which is well absorbed sublingually and generally well tolerated.\u00a0<sup id=\"cite_ref-trib_33-2\" class=\"reference\"><\/sup>Such forms are particularly useful for breakthrough cancer pain episodes, which are often rapid in onset, short in duration and severe in intensity.<sup id=\"cite_ref-35\" class=\"reference\"><\/sup>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=47145\" rel=\"attachment wp-att-47145\"><img class=\"wp-image-47145 aligncenter\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/01\/Screen-Shot-2022-04-07-at-3.32.02-pm.png\" alt=\"\" width=\"300\" height=\"94\" \/><\/a>\r\n\r\nA.Menarini Pty Ltd. Level 8, 67 Albert Avenue, Chatswood NSW 2067. Tel: 1800 644 542.ABN 62 116 935 758. <span class=\"il\">ABS<\/span>-AU-<span class=\"gmail_default\">1747<\/span> June 2022.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/04\/Abstral_logos_Red-Only.jpg","cat_name":"I would like a representative to contact me regarding Abstral training","slug":"abstral-training","sku_code":null}],"asthma":[{"ID":"60890","post_title":"EASYHALER\u00ae DRY POWDER INHALER","post_content":"<div>\u2022 Easyhaler\u00ae is an environmentally sustainable new multidose reservoir-type dry powder inhaler (DPI), for the treatment of asthma and chronic obstructive pulmonary disease (COPD)\u2074.<\/div>\r\n<div>\u2022 Greenhouse gas emissions throughout the Easyhaler\u00ae product life cycle have been reduced and the remaining and currently unavoidable emissions are offset, making Easyhaler\u00ae a carbon neutral product\u00b9.<\/div>\r\n<div>\u2022 Easyhaler\u00ae is simple to use and easy to learn, so patient preference is high\u2075 \u2076.<\/div>\r\n<div>\r\n\r\n\u2022 Most patients generate sufficient inspiratory flow to effectively use Easyhaler\u00ae \u2077.\r\n\r\n<\/div>\r\n<div><strong><a href=\"https:\/\/vimeo.com\/937514483?share=copy\">CLICK HERE<\/a> <\/strong>to watch Easyhaler\u00ae in action.<\/div>\r\n<div>\r\n\r\n<strong><a href=\"https:\/\/vimeo.com\/917316799?share=copy\">CLICK HERE<\/a><\/strong> to learn how Easyhaler\u00ae is a sustainable choice.\r\n\r\n<\/div>\r\n<div>The simple patient instructions for use are:<\/div>\r\n<ul>\r\n \t<li>SHAKE, CLICK, INHALE.<\/li>\r\n \t<li>It is important to shake Easyhaler\u00ae in an upright position 3\u20135 times before use.<\/li>\r\n \t<li>If a patient accidentally clicks Easyhaler\u00ae or clicks it twice, tap the mouthpiece to empty the powder onto a tabletop or the palm of your hand and start again with the steps; SHAKE, CLICK, INHALE.<\/li>\r\n \t<li>Easyhaler\u00ae contains a dose counter and is packaged with a protective cover and should be placed in the protective cover when not in use\u00b2 \u00b3.<\/li>\r\n<\/ul>\r\n<div>\r\n\r\nTHERE ARE TWO PRODUCTS IN THE EASYHALER\u00ae RANGE\r\n\r\n<\/div>\r\n<div><strong>BUFOMIX EASYHALER\u00ae<\/strong> (Budesonide Formoterol fumarate dihydrate) available in two strengths\u00b3.<\/div>\r\n<div>\u2022 BUFOMIX EASYHALER\u00ae 200\/6 budesonide 200 \u00b5g and formoterol fumarate dihydrate 6 \u00b5g.<\/div>\r\n<div>\r\n\r\n\u2022 BUFOMIX EASYHALER\u00ae 400\/12 budesonide 400 \u00b5g and formoterol fumarate dihydrate 12 \u00b5g.\r\n\r\n<\/div>\r\n<div><strong><a href=\"https:\/\/vimeo.com\/930144434\/3b24893e07?share=copy\">CLICK HERE<\/a> <\/strong>to watch Bufomix Easyhaler\u00ae instructional video.<\/div>\r\n<div><strong><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/How-to-use-Easyhaler-instruction-pad-English_Bufomix_March-2024-EH_AU_2024_04.pdf\">CLICK HERE<\/a> <\/strong>to access Bufomix Easyhaler\u00ae how to use instructions.<\/div>\r\n<div>\r\n\r\n<strong><a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;amp;t=pi&amp;amp;q=bufomix\">CLICK HERE<\/a> <\/strong>to review Bufomix Easyhaler\u00ae product information before prescribing.\r\n\r\n<img class=\"alignnone size-full wp-image-60895\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/bufo.png\" alt=\"\" width=\"963\" height=\"67\" \/>\r\n\r\n<\/div>\r\n<div><\/div>\r\n<div><strong>SALFLUMIX EASYHALER<\/strong> (Fluticasone propionate \/ salmeterol xinafoate) available in two strengths\u00b2.<\/div>\r\n<div>\u2022 SALFLUMIX EASYHALER 250\/50 salmeterol 50 \u00b5g (as xinafoate) and 250\u00b5g fluticasone propionate.<\/div>\r\n<div>\r\n\r\n\u2022 SALFLUMIX EASYHALER 500\/50 salmeterol 50 \u00b5g (as xinafoate) and 500\u00b5g fluticasone propionate.\r\n\r\n<\/div>\r\n<div><strong><a href=\"https:\/\/vimeo.com\/930144396\/6a5d98cdf7?share=copy\">CLICK HERE<\/a><\/strong> to watch Salflumix Easyhaler\u00ae instructional video.<\/div>\r\n<div><strong><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/How-to-use-Easyhaler-instruction-pad-English_Salflumix-March-2024-EH_AU_2024_05.pdf\">CLICK HERE<\/a><\/strong> to access Salflumix Easyhaler\u00ae how to use instructions.<\/div>\r\n<div>\r\n\r\n<a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;amp;t=pi&amp;amp;q=salflumix%20easyhaler\"><strong>CLICK HERE<\/strong><\/a> to review Bufomix Easyhaler\u00ae product information before prescribing.\r\n\r\n<img class=\"alignnone size-full wp-image-60895\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/bufo.png\" alt=\"\" width=\"963\" height=\"67\" \/>\r\n\r\n<\/div>\r\n<div>\r\n\r\nReferences:\r\n\r\n<\/div>\r\n<div>\r\n\r\nReferences: 1. Carbon Neutral Product Certificate for Easyhaler\u00ae product range. Available on request from Orion Pharma. 2. Salflumix Easyhaler\u00ae Product Information, August 18, 2023. 3. Bufomix Easyhaler\u00ae Product Information, July 17, 2023. 4. Inget M, Hisinger-M\u00f6lk\u00e4nen H, Howard M, L\u00e4helm\u00e4 S, Paronen N. Cradle-to-Grave Emission Reduction for Easyhaler\u00ae Dry Powder Inhaler Product Portfolio. Pulm Ther. 2023 Dec;9(4):527-533. 5. G\u00e1lffy G, Szilasi M, Tam\u00e1si L. Effectiveness and Patient Satisfaction with Budesonide\/Formoterol Easyhaler\u00ae Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes. Pulm Ther. 2019;5(2):165\u201377. 6. G\u00e1lffy G, Mezei G, N\u00e9meth G, Tam\u00e1si L, M\u00fcller V, Selroos O, Orosz M. Inhaler competence and patient satisfaction with Easyhaler\u00ae: results of two real-life multicentre studies in asthma and COPD. Drugs R D. 2013;13(3):215\u201322. 7. Malmberg LP, Rytil\u00e4 P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010.\r\n\r\n<\/div>\r\n<div>Easyhaler\u00ae is a registered trademark of Orion Corporation Finland.<\/div>\r\n<div>Orion Pharma, Level 24, Tower 3, 300 Barangaroo Avenue, Sydney NSW 2000 PH:+61 8067 8704 EMAIL: contactusaustralia@orionpharma.com WEB: www.orionpharma.com.au To report an adverse event, or for medical information EMAIL: medical.ANZ@pharmalex.com or PH: 1800 861 913. Date of preparation May 2024. EH_AU_2024_10<\/div>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Packages-all-EHV1.pdf.png","cat_name":"Asthma","slug":"asthma","sku_code":null}],"pregnancy":[{"ID":"60931","post_title":"NATALIS PREGNANCY MULTIVITAMIN","post_content":"<p class=\"pf0\"><span class=\"cf0\"> Natalis is an Australian Made pregnancy multivitamin formulated with 19 important nutrients including folic acid, iron and iodine to help support increased nutritional needs at different stages of pregnancy as well as supporting the baby\u2019s health.<\/span><\/p>\r\nPre-Conception and Pregnancy- It may be difficult for some pregnant women to eat a balanced diet, especially if they have morning sickness. Natalis is designed especially for pregnant women or women who are trying to fall pregnant.\r\n\r\nBreastfeeding- Breastfeeding a baby places new demands on the mother for increased nutrient requirements. Natalis contains a blend of essential nutrients to support women in meeting the increased nutritional demands of breastfeeding.<!--EndFragment -->\r\n\r\n<iframe title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/ZdhtflA8a54?si=5wI9KZjkbloLl5vI\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe>\r\n\r\nIngredients:\r\n\r\n<img class=\"alignnone size-full wp-image-60932\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/table-natalis.png\" alt=\"\" width=\"375\" height=\"792\" \/>\r\n\r\nClick <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/43B113-Natalis-GP-Leave-Behind-V5.pdf\">here<\/a> for Natalis fact sheet\r\n\r\nDose and directions for use:\r\n<ul>\r\n \t<li>Take Natalis for at least one month before pregnancy, throughout pregnancy and whilst breastfeeding.<\/li>\r\n \t<li>Take one tablet daily with main meal, or as directed by your healthcare professional.<\/li>\r\n<\/ul>\r\nWarnings:\r\n<ul>\r\n \t<li>This product contains Selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.<\/li>\r\n \t<li>Do not exceed the stated dose of folic acid, except on medical advice.<\/li>\r\n \t<li>If you have had a baby with a neural tube defect\/spina bifida, seek specific medical advice.<\/li>\r\n \t<li>Vitamins should not replace a balanced diet.<\/li>\r\n \t<li>Contains sugars and soya bean products.<\/li>\r\n<\/ul>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/65N001-Natalis-Multi-tabs_AUNZ-10s-CARTON-V3-Render.png","cat_name":"Pregnancy","slug":"pregnancy","sku_code":null}],"dietary-supplements":[{"ID":"45376","post_title":"a2 MILK\u2122 FULL CREAM UHT","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/a2milk_hcp-booklet_mar21\/\">a2 Milk HCP Booklet<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/a2nutrition4professionals.com.au\/\">HCP website<\/a>\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45381\" rel=\"attachment wp-att-45381\"><img class=\"alignleft size-full wp-image-45381\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.21.40-pm.png\" alt=\"\" width=\"743\" height=\"1052\" \/><\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=45382\" rel=\"attachment wp-att-45382\"><img class=\"alignleft size-full wp-image-45382\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Screen-Shot-2021-12-20-at-7.22.04-pm.png\" alt=\"\" width=\"745\" height=\"783\" \/><\/a>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/UHT-packshot.png","cat_name":"Dietary supplements","slug":"dietary-supplements","sku_code":null},{"ID":"56979","post_title":"OSTELIN VITAMIN D 7000IU","post_content":"[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/231018_SAN142_Ostelin_1080p_MAT-1.mp4\"][\/video]\r\n\r\n<img class=\"alignnone size-medium wp-image-57172\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Ostelin-TYPE-P-300x76.png\" alt=\"\" width=\"300\" height=\"76\" \/>\r\n\r\nOstelin Specialist Range Vitamin D 7000iu is formulated to provide practitioners and patients with the convenience of a one-a-week vitamin D supplement.\r\n\r\nVitamin D is indicated for patients diagnosed with a vitamin D deficiency, and for preventing deficiency in high-risk individuals under medical practitioner supervision.\r\n\r\nFor more information, please see the <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Ostelin_Vitamin_D_7000IU_CMI-1.pdf\">Ostelin Specialist Range 7000iu Product Information leaflet.<\/a>\r\n\r\n<a href=\"#_ftn2\" name=\"_ftnref2\"><\/a>\r\n\r\nVitamin D is a fat-soluble vitamin found in the diet in eggs, dairy and fish<span style=\"font-size: 50%; vertical-align: super;\">1<\/span>.\u00a0 \u00a0Most adults are unlikely to obtain more than 5-10% of their vitamin D requirement from dietary sources. The main source of vitamin D for people residing in Australia and New Zealand is exposure to sunlight.\r\n\r\n<a href=\"#_ftn2\" name=\"_ftnref2\"><\/a>\r\n\r\n<a href=\"#_ftn2\" name=\"_ftnref2\"><\/a>\r\n\r\n<a href=\"#_ftn2\" name=\"_ftnref2\"><\/a>\r\n\r\n<a href=\"#_ftn2\" name=\"_ftnref2\"><\/a>\r\n\r\nIndicated for those diagnosed with a vitamin D deficiency, Ostelin Specialist Range Vitamin D 7000IU is a schedule 3 registered medicine. Recommended for those patients who require vitamin D supplementation on an ongoing basis, Ostelin Specialist Range Vitamin D 7000IU is a convenient alternative to a daily program of 1000IU supplementation.\r\n\r\nAlso indicated for those patients at high risk of vitamin D deficiency, Ostelin Specialist Range Vitamin D 7000IU \u00a0including those who<sup>2,3<\/sup>:\r\n<ul>\r\n \t<li>Wear covered dress for cultural, religious or sun-protection reasons.<\/li>\r\n \t<li>are housebound (particularly the elderly).<\/li>\r\n \t<li>have naturally dark skin tones.<\/li>\r\n \t<li>work in environments with limited to no sun exposure (such as office workers, shift workers and the like).<\/li>\r\n \t<li>who regularly avoid sun exposure due to a long-term health condition or disability.<\/li>\r\n \t<li>with additional metabolic concerns such as obesity.<\/li>\r\n<\/ul>\r\n<strong>Product Information <\/strong>\r\n\r\nSuitable for:\r\n<ul>\r\n \t<li>the treatment of vitamin D deficiency in adults and adolescents as directed by your medical practitioner or pharmacist.<\/li>\r\n \t<li>For the prevention of vitamin D deficiency in high-risk individuals under the supervision of a medical practitioner.<\/li>\r\n<\/ul>\r\nIngredient &amp; dosing:\r\n<ul>\r\n \t<li>Contains Colecalciferol 7000iu (175mcg)<\/li>\r\n \t<li>One-a-week dose.<\/li>\r\n \t<li>Available in 24 capsules and 48 capsules.<\/li>\r\n \t<li>No added yeast, gluten, lactose, sugar, flavours, sweeteners, or dairy products.<\/li>\r\n \t<li>Halal certified product.<\/li>\r\n \t<li>This ingredient is derived from the lanolin of sheep\u2019s wool.<\/li>\r\n<\/ul>\r\nQuality Promise:\r\n<ul>\r\n \t<li>This product is made in Australia from carefully selected, high quality ingredients.<\/li>\r\n \t<li>Ostelin proudly sources high quality ingredients and carefully create our products following strict quality controls.<\/li>\r\n<\/ul>\r\nProduct disclaimers\r\n<ul>\r\n \t<li>Do not use in children under 12 years of age.<\/li>\r\n \t<li>Do not use if blister foil or carton seal is broken.<\/li>\r\n \t<li>Contains soya products.<\/li>\r\n \t<li>Store below 25 degrees Celsius.<\/li>\r\n<\/ul>\r\n&nbsp;\r\n<ol>\r\n \t<li><small><small>Mistretta et al. Vitamin D2 or Vitamin D3? The Journal of Internal Medicine. 2008; 29(10):815-820. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0248866308001434?via%3Dihub\">Vitamin D2 or vitamin D3? - ScienceDirect<\/a><\/small><\/small><\/li>\r\n \t<li><small><small>Nowson CA et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust 2012; 196 (11): 686\u201387. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja11.10301\">Vitamin D and health in adults in Australia and New Zealand: a position statement - Nowson - 2012 - Medical Journal of Australia - Wiley Online Library<\/a><\/small><\/small><\/li>\r\n \t<li><small><small>Park et al. Vitamin D and Metabolic Diseases: Growing Roles of Vitamin D. J Obes Metab Syndr. 2018 Dec; 27(4):223-32<\/small><\/small><\/li>\r\n<\/ol>\r\nFor more information on the Ostelin range download our <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/005484-Ostelin-GP-Detailing-Range-Folder-2023-MAT-AU-2302091-2_HR-Crops-Layers.pdf\">Product Range Portfolio<\/a>\r\n\r\n<img class=\"alignnone size-medium wp-image-57170\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Logo-PNG-1-300x138.png\" alt=\"\" width=\"300\" height=\"138\" \/>\r\n\r\nOstelin Specialist Range Vitamin D 7000IU is made by Sanofi in Virginia, Queensland.\r\n\r\nDriven by science, Sanofi is a leading force in the Australian healthcare industry, providing vaccines, prescription and over the counter medicines, along with vitamins, minerals and supplements to Australian pharmacies. At Sanofi we chase the miracles of science to change people\u2019s lives<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>.\r\n<ol>\r\n \t<li><small><small>Ref: <a href=\"https:\/\/www.sanofi.com\/en\/about-us\/our-purpose\">Our Purpose and Identity - Sanofi<\/a><\/small><\/small><\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Ostelin-7000iu-Pack-shot-with-Pharmacist-disclaimer-1.jpg","cat_name":"Dietary supplements","slug":"dietary-supplements","sku_code":null},{"ID":"55188","post_title":"VITAMIN D LIPO-SACHETS","post_content":"<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/VitD-LipoSachet-CMYK-horizontal-logo.png\"><img class=\"aligncenter size-full wp-image-55192\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/VitD-LipoSachet-CMYK-horizontal-logo.png\" alt=\"\" width=\"4688\" height=\"270\" \/><\/a>\r\n\r\nhttps:\/\/youtu.be\/vvhjAnONWYo\r\n\r\nCLICK TO DOWNLOAD <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Lipo-Sachets-digital-detail-aid.pdf\">Lipo-Sachets digital detail aid<\/a>\r\n\r\nCLICK TO DOWNLOAD <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/35834-VitaminD-consumer-tearpad-leaflet-A6_F.pdf\">VitaminD Consumer tearpad leaflet<\/a>\r\n\r\n&nbsp;\r\n<p class=\"p1\"><strong>Vitamin D Lipo-Sachets indications<\/strong><\/p>\r\nSuperior absorption compared to standard vitamin D3 capsules<sup>2<\/sup>\r\n\r\nHelps enhance general health and wellbeing\r\n\r\nAids healthy bone development\/growth\/building\r\n\r\nVitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life\r\n\r\nHelps enhance immune system function\r\n\r\nHelps enhance healthy muscle function\r\n\r\nsupport nervous system function\r\n\r\nsupport healthy foetal development\r\n\r\n&nbsp;\r\n\r\nWho could benefit from taking vitamin D?\r\n<ul>\r\n \t<li>Those looking to support their immune system<\/li>\r\n \t<li>Those with low exposure to sunlight due to their lifestyle<\/li>\r\n \t<li>Those who covers most of their skin due to cultural or religious reasons<\/li>\r\n \t<li>In autumn and winter periods because of reduced amounts of sunlight<\/li>\r\n \t<li>People using cosmetic with UV filters or sunscreen<\/li>\r\n \t<li>For people with darker skin \u2013 due to high melanin in the skin<\/li>\r\n \t<li>Those who want to supplement their diet with vitamin D<\/li>\r\n<\/ul>\r\nNo alcohol, gluten, GMO, artificial colours, artificial flavours. Vegetarian, halal and pregnancy friendly\r\n\r\nNo added sugars*\r\n\r\n<em>* Contains naturally occurring sugars.<\/em>\r\n\r\n<em>\u00a0<\/em>\r\n<ol>\r\n \t<li><em>Da\u0142ek P, et al., Nanomedicine: NBM 2022;43:102552.<\/em><\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Vitamin-D-Lipo-box-left-side-MELON-copy.png","cat_name":"Dietary supplements","slug":"dietary-supplements","sku_code":null}],"dermatology":[{"ID":"56512","post_title":"TISSUE REPAIR","post_content":"TR Pro+ is a hydrogel that has been specifically formulated to assist skin healing and has been shown to improve wrinkling and elastosis by up to 40% after 5 days use<sup>1<\/sup>.\u00a0 TR Pro+ contains the patented ingredient, Glucoprime, which is a large beta-glucan polysaccharide purified from baker\u2019s yeast.\r\n\r\nThe ability of beta-glucans to modulate the immune system has been known for many years<sup>2<\/sup>, but researchers have been challenged in isolating a glucan that did not breakdown during the purification process.\u00a0 Over more than a decade Tissue Repair has developed the expertise to generate a beta glucan that is insoluble and more closely resembles the native size, making it a more effective immune modulator.\u00a0 TR Pro+ is readily absorbed into the skin and can activate macrophages which in turn stimulates the production of cytokines, growth factors and collagen, which together benefit healing skin<sup>2<\/sup>.\r\n\r\nTR Pro+ has been used in a double-blinded controlled study on patients who underwent a laser skin resurfacing procedure<sup>1<\/sup>.\u00a0 After using TR Pro+ for 5 days they were examined (at day 28) and found to have improved skin quality compared to the placebo gel, based on superior wrinkling and elastosis.\u00a0 The study has been published in the peer-reviewed journal, Dermatologic Surgery.\r\n\r\nIn 2022 a real-world evidence study was done in collaboration with 12 dermatology clinics in Australia<sup>3<\/sup>.\u00a0 TR Pro+ was used as an aftercare treatment for a range of aesthetic and medical procedures including laser, skin needling, light treatments, skin cancer removal and biopsy.\u00a0 The feedback was overwhelmingly positive with 85% of patients considering that their skin was healing well or very well.\u00a0 Of those patients who had had prior procedures, 100% rated TR Pro+ as good or better than their previous aftercare product.\r\n\r\nTR Pro+ offers a broader range of benefits than most other aftercare products.\u00a0 TR Pro+ dries to form a light biofilm and can reduce water evaporation and provide deep hydration.\u00a0 The biofilm is semi permeable so allows heat to dissipate and oxygen to transfer across the skin.\u00a0 The haemostatic property of the hydrogel can also help manage bleeding.\u00a0 While the formulation is relatively simple and does not contain fragrances, the macrophage activation prevents infection.\u00a0 TR Pro+ can be applied immediately following a procedure and is particularly effective when used on broken skin.\r\n\r\nA range of case studies for both aesthetic and medical treatments are described in the attached document.\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/RWE-Outcomes-0922.pdf\">Real World Evidence Study (2002)<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Dermatologic-Surgery-Study.pdf\">Dermatologic Surgery Study<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/Patient-Brochure.pdf\">Patient Brochure<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/TR-Mkt003-Consumer-Information-v10-FINAL-290823.pdf\">Consumer Information Leaflet<\/a>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/10\/TR-Pro-product-information-mySamples-091123.pdf\">TR Pro+ product information<\/a>\r\n\r\n&nbsp;\r\n\r\n<small><small>1. Wu DC et al. Dermatol Surg. 2022 Dec 1;48(12):1312-1316<\/small><\/small>\r\n\r\n<small><small>2. Du B, et al. A Concise Review on the Molecular Structure and Function Relationship of \u03b2-Glucan. Int J Mol Sci. 2019 Aug 18;20(16):4032.<\/small><\/small>\r\n\r\n<small><small>3. Patient Experiences Using TR Pro+. Vivacity Health and IQVIA. 2021<\/small><\/small>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/11\/tr-pro-10g-product-2023-1-600x707-1.jpg","cat_name":"Dermatology","slug":"dermatology","sku_code":null},{"ID":"49105","post_title":"AKLIEF","post_content":"CLICK to view the <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/07\/Aklief-75g-PI.pdf\">AKLIEF PI<\/a>\r\n\r\nCLICK to access the <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/07\/Aklief_Precision-Wins_eDetailer_May-2022.pdf\">Aklief eDetailer<\/a>\r\n<div class=\"accordion-group\">\r\n<div id=\"faqEleven\" class=\"accordion-content collapse in\" aria-labelledby=\"faqTitleEleven\" data-parent=\"#faqAccordion\" aria-expanded=\"true\">\r\n<div>The active ingredient in AKLIEF Cream is trifarotene, an innovative retinoid molecule that targets important factors that cause acne.<sup>1 <\/sup>Trifarotene works by specifically targeting the retinoic acid receptor gamma (RAR-\u03b3), the most prevalent receptor in the skin, to reduce inflammation and target other important factors that cause acne.<\/div>\r\n<\/div>\r\n<\/div>\r\n<div><\/div>\r\n<div><a href=\"https:\/\/mysamples.com.au\/aklief_precision-wins_edetailer_may-2022-2\/\"><img class=\"aligncenter size-full wp-image-49110\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/07\/Aklief_Precision-Wins_eDetailer_May-2022-scaled.jpg\" alt=\"\" width=\"2560\" height=\"1920\" \/><\/a><\/div>\r\n<div><\/div>\r\n<div><\/div>\r\n<div class=\"accordion-group\">\r\n<div id=\"faqTitleTwelve\" class=\"accordion-title\"><\/div>\r\n<\/div>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/07\/aklief-30g.png","cat_name":"Dermatology","slug":"dermatology","sku_code":null}],"nasal-sinus":[{"ID":"55902","post_title":"SINUPRET\u00ae","post_content":"[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/07\/Sinupret23-ADULTS-1920x1080_05-2.mp4\"][\/video]\r\n\r\n&nbsp;\r\n\r\nClick to download the <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/07\/Sinupret-Detailer-A5-Brochure-FINAL-SP23029.pdf\">Sinupret Detailer<\/a>\r\n<p class=\"p1\">Sinupret\u00ae is available as:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Sinupret\u00ae forte, coated tablets for adults and children 12 years and over<\/li>\r\n \t<li class=\"p1\">Sinupret\u00ae Syrup, an oral liquid for adults and children 2 years and over<\/li>\r\n<\/ul>\r\nSinupret\u00ae, with its unique 5-plant formula has secretolytic and anti-inflammatory effects, helping to clear nasal congestion and reduce the duration of sinus headaches.\r\n<p class=\"p1\">Sinupret\u00ae forte is clinically proven to relieve symptoms associated with sinusitis, when combined with antibiotics and nasal decongestant sprays.<sup>1 <\/sup>Similarly, Sinupret\u00ae Syrup also offers clinically proven sinusitis relief in children.<sup>2-4<\/sup><\/p>\r\n<p class=\"p1\">It is the No. 1 market leader in German-speaking Europe (Germany, Austria and Switzerland).<sup>5<\/sup><\/p>\r\n<p class=\"p1\">Sinupret\u00ae loosens mucus, opens the nose and clears the head. It helps restore mucociliary clearance by:<\/p>\r\n\r\n<ul>\r\n \t<li>Hydrating the respiratory epithelium via improved chloride secretion and,<\/li>\r\n \t<li>Promoting the break up of secretions - a process known as secretolytic.<\/li>\r\n<\/ul>\r\n<p class=\"p1\">Sinupret\u00ae forte - active substances:<\/p>\r\n<p class=\"p1\">Each coated tablet contains:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Gentiana lutea root (gentian root) powder 12 mg<\/li>\r\n \t<li class=\"p1\">Primula veris (German Medicinal Product Codex) flower (cowslip) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Rumex crispus herb (sorrel) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Sambucus nigra flower (elder flower) powder 36 mg<\/li>\r\n \t<li class=\"p1\">Verbena officinalis herb (vervain) powder 36 mg<\/li>\r\n \t<li class=\"p1\"><b>Contains:<\/b> Sugars and lactose.<\/li>\r\n<\/ul>\r\n<p class=\"p1\">Sinupret\u00ae Syrup - active substances:<\/p>\r\n<p class=\"p1\">1 mL of Sinupret\u00ae Syrup contains 0.417 g of herbal extract equivalent to dry:<\/p>\r\n\r\n<ul>\r\n \t<li class=\"p1\">Gentiana lutea root 0.85 mg<\/li>\r\n \t<li class=\"p1\">Primula veris (German Medicinal Product Codex) flower 2.54 mg<\/li>\r\n \t<li class=\"p1\">Rumex crispus herb 2.54 mg<\/li>\r\n \t<li class=\"p1\">Sambucus nigra flower 2.54 mg<\/li>\r\n \t<li class=\"p1\">Verbena officinalis herb 2.54 mg<\/li>\r\n \t<li class=\"p1\"><b>Contains: <\/b>cherry flavour, ethanol, liquid maltitol.<\/li>\r\n<\/ul>\r\nFor further information visit <a href=\"http:\/\/www.sinupret.com.au\">the Product website<\/a>\r\n\r\nReferences*\r\n<p class=\"p1\">1. Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed. 2006; 13(2):78\u201387. (Partly funded by a grant from Bionorica, Neumarkt, Germany)<\/p>\r\n<p class=\"p1\">2. Virgin F et al. The bioflavonoid compound, Sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010;120(5):1051-6.<\/p>\r\n<p class=\"p1\">3. Popovich V and Beketova H. Results of a randomised controlled study on the efficacy of a combination of saline irrigation and Sinupret syrup phytopreparation in the treatment of acute viral rhinosinusitis in children aged 6 to 11 years. Clinical Phytoscience 2018;4:21. https:\/\/doi.org\/10.1186\/s40816-018-0082-y.<\/p>\r\n<p class=\"p1\">4. Popovich V and Koshel I. Sinupret\u00ae as add-on therapy to saline irrigation for children with acute post-viral rhinosinusitis. Clinical Phytoscience 2017;3:10. DOI 10.1186\/s40816-017-0047-6.<\/p>\r\n<p class=\"p1\">5. QVIA. Pharmacy sell-out in euro on retail price level and sales in units, 2021; CH:IQVIA. Sales in euro on ex-manufacturer price level and sales in units, YTD 06.2021; AT:IQVIA, Pharmacy sell-out in euro on retail price level and sales in units. 2021.<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/05\/Sinupret-Forte-Group-Image.png","cat_name":"Nasal \/ Sinus","slug":"nasal-sinus","sku_code":null}],"gout":[{"ID":"52709","post_title":"ADENURIC\u00ae (febuxostat)","post_content":"Access the Adenuric<sup>\u00ae<\/sup> PI <a href=\"https:\/\/www.guildlink.com.au\/gc\/ws\/fk\/pi.cfm?product=fkpadent\">here<\/a>\r\n\r\nThe recommended oral dose of ADENURIC is 40 mg or 80 mg once daily with or without food. The recommended starting dose of ADENURIC is 40 mg once daily. If serum uric acid (sUA) is greater than 357 micromole\/L (6 mg\/dL) after 2-4 weeks, ADENURIC 80 mg once daily is recommended. The 80 mg tablet can be split into two equal halves in order to provide a 40 mg dose. Prescribers should advise patients on how to break the tablets in half. Testing for the target serum uric acid level of less than 357 micromole\/L (6 mg\/dL) may be performed as early as two weeks after initiating ADENURIC therapy. Gout flare prophylaxis of up to 6 months is recommended (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Acute Gouty Attacks (gout flares)).\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Adenuric-PBS.png\"><img class=\"aligncenter size-full wp-image-52719\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Adenuric-PBS.png\" alt=\"\" width=\"1350\" height=\"124\" \/><\/a>\r\n\r\nPlease review the approved Product information before prescribing. The product information can be accessed at\u00a0<a href=\"http:\/\/www.menarini.com.au\/PI\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=http:\/\/www.menarini.com.au\/PI&amp;source=gmail&amp;ust=1664932454879000&amp;usg=AOvVaw1kqYC8khPQgMQYgHrVKhUF\">www.menarini.com.au\/PI<\/a>\r\n\r\nApproval code: ADE-AU-1907","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/03\/Screen-Shot-2023-03-01-at-4.26.23-PM.png","cat_name":"Gout","slug":"gout","sku_code":null}],"mens-health":[{"ID":"3697","post_title":"TESTOGEL\u00ae","post_content":"Testogel\u00ae\u00a0is indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.\r\n\r\n<a href=\"https:\/\/vimeo.com\/303199072\">Please click here to watch a video on Testogel\u00ae<\/a>\r\n\r\nTestogel restores and maintains testosterone levels in the normal range.\r\n\r\nIn men with hypogonadism, Testogel\u00ae can:\r\n<ul>\r\n \t<li>Improve mood<\/li>\r\n \t<li>Improve sexual function<\/li>\r\n \t<li>Improve body composition<\/li>\r\n \t<li>Increase muscle strength<\/li>\r\n \t<li>Strengthen bones<\/li>\r\n \t<li>Improve blood sugar, blood pressure and bad cholesterol<\/li>\r\n \t<li>Improve overall satisfaction with life<\/li>\r\n<\/ul>\r\nTestogel\u00ae is absorbed through the skin and then slowly moves into the blood stream.\r\n\r\nTestogel\u00ae is natural \u201cbody identical\u201d testosterone.\u00a0It mimics the normal daily rhythm of natural testosterone production with daily application.\r\n<div class=\"ref-sup-wrap\"><\/div>\r\n<img class=\"alignnone size-full wp-image-63028\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/06\/testogel-1.png\" alt=\"\" width=\"787\" height=\"633\" \/>","guid":"http:\/\/mysamples.benslater.me\/wp-content\/uploads\/2018\/06\/testogel.png","cat_name":"Mens health","slug":"mens-health","sku_code":null}],"breakthrough-cancer-pain":[{"ID":"38472","post_title":"ABSTRAL (Fentanyl citrate)","post_content":"<p class=\"p1\">Breakthrough cancer pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.<\/p>\r\n[video width=\"1920\" height=\"1080\" mp4=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/05\/ABS-AU-1404-How-to-Take-Abstral-patient-video-2.mp4\"][\/video]\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK ABOVE<\/strong><\/span>\u00a0to view \"How to take\" video\r\n\r\n<span style=\"text-decoration: underline;\"><strong>CLICK HERE<\/strong><\/span> to visit the Abstral website\r\n<p class=\"p1\">ABSTRAL should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain.<\/p>\r\n<p class=\"p1\">Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily or an equivalent analgesic dose of another opioid for a week or longer.<\/p>\r\n<p class=\"p1\">ABSTRAL sublingual tablets should be administered directly under the tongue at the deepest part. ABSTRAL sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.<\/p>\r\nSublingual Abstral dissolves quickly and is absorbed through the sublingual\u00a0mucosa to provide rapid\u00a0analgesia. <sup id=\"cite_ref-trib_33-0\" class=\"reference\"><\/sup>Fentanyl is a highly lipophilic compound,<sup id=\"cite_ref-trib_33-1\" class=\"reference\"><\/sup><sup id=\"cite_ref-34\" class=\"reference\"><\/sup> which is well absorbed sublingually and generally well tolerated.\u00a0<sup id=\"cite_ref-trib_33-2\" class=\"reference\"><\/sup>Such forms are particularly useful for breakthrough cancer pain episodes, which are often rapid in onset, short in duration and severe in intensity.<sup id=\"cite_ref-35\" class=\"reference\"><\/sup>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/?attachment_id=47145\" rel=\"attachment wp-att-47145\"><img class=\"wp-image-47145 aligncenter\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/01\/Screen-Shot-2022-04-07-at-3.32.02-pm.png\" alt=\"\" width=\"300\" height=\"94\" \/><\/a>\r\n\r\nA.Menarini Pty Ltd. Level 8, 67 Albert Avenue, Chatswood NSW 2067. Tel: 1800 644 542.ABN 62 116 935 758. <span class=\"il\">ABS<\/span>-AU-<span class=\"gmail_default\">1747<\/span> June 2022.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/04\/Abstral_logos_Red-Only.jpg","cat_name":"Breakthrough Cancer Pain","slug":"breakthrough-cancer-pain","sku_code":null}],"eye-care":[{"ID":"50181","post_title":"NOVATEARS\u00ae","post_content":"Click to view the <a href=\"https:\/\/mysamples.com.au\/31942-novatears-gpdetailer-a4-singlepage-f\/\">NovaTears Detail aid<\/a>\r\n\r\nClick to view the <a href=\"https:\/\/mysamples.com.au\/34470-consumer-flyer-au-a5-148x210-v1\/\">Patient Flyer<\/a>\r\n\r\nView the NovaTears<sup>\u00ae<\/sup> Product Information video below.\r\n\r\n<iframe title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/tpYqOwZBI24\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nNovaTears\u00ae is a patented preservative-free eye lubricant, which acts as a lipid layer substitute and evaporative barrier for improved tear film stability and quality.\r\n\r\nPreservative, Phosphate &amp; Aqueous Free. Spreads quickly &amp; easily on the eye\r\n\r\nPleasant, warm silky feeling with no stinging or blurring\r\n\r\nClinically validated with significant improvements in signs &amp; symptoms for patients with Evaporative Dry Eye Disease &amp; Meibomian Gland Dysfunction.<sup>1,2<\/sup>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\nClick to visit the <a href=\"http:\/\/www.mydryeyes.com.au\">Product Website<\/a>\r\n\r\n&nbsp;\r\n\r\n<strong>NovaTears<sup>\u00ae<\/sup> is a PBS Listed Product<\/strong>\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2022-09-19-at-4-55-02-pm\/\"><img class=\"aligncenter size-full wp-image-50278\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/Screen-Shot-2022-09-19-at-4.55.02-PM.png\" alt=\"\" width=\"2012\" height=\"142\" \/><\/a>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\n&nbsp;\r\n\r\n<sup>1.Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease \u2013 A Prospective, Multicenter Noninterventional Study.\u201d Journal of Ocular Pharmacology and Therapeutics 31 (8), 498-503(2015). 2. Steven, Philipp, et al. \u201cSemifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.\u201d Journal of Ocular Pharmacology and Therapeutics. 33(9), 678-685(2017). Sponsored by Novaliq GmbH.<\/sup>\r\n<div class=\"page\" title=\"Page 1\">\r\n<div class=\"section\">\r\n<div class=\"layoutArea\">\r\n<div class=\"column\">\r\n\r\nAFT Pharmaceuticals Pty Ltd, Sydney | ABN: 29105636413| Freephone: 1800 AFTPHARM | Freefax: 1800 041 026 Email: sydney.reception@aftpharm.com | Website: <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/09\/NOVA_TEARS_Bottle_2000x1000_72dpi.jpg","cat_name":"Eye Care","slug":"eye-care","sku_code":null}],"infant-formula":[{"ID":"51616","post_title":"a2 GENTLE GOLD\u2122 PREMIUM INFANT FORMULA STAGE 1","post_content":"Click link to view\u00a0<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/08\/Infant-Formula-Sample-Information.pdf\">Infant Formula Sample Information<\/a>\r\n\r\nClick to view\u00a0<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/11\/a2-Gentle-Gold-Infant-formula-Stage-1-product-information-032024.pdf\">a2 Gentle Gold Premium\u2122 Infant Formula Stage 1 product information\u00a0<\/a>\r\n<div>At The a2 Milk Company, we believe breastfeeding is best to provide the ideal nutrition for babies, in addition to providing other important health benefits.<\/div>\r\n<div>We also understand that breastfeeding may not be an option for everyone.<\/div>\r\n<div>To support families on their feeding journey we recommend that they seek advice from their health care professional. As a first step, good nutrition is important during pregnancy, post birth to support recovery, and whilst breastfeeding.<\/div>\r\n<div>Introducing infant formula either partially or exclusively may reduce breastmilk supply which can be difficult to re-establish. The social and financial impacts, such as the potential cost of providing formula until an infant is 12 months old, should be considered when exploring feeding options.<\/div>\r\n<div>To ensure safe nutrition for infants when using any infant formula, always prepare and use as per the preparation instructions as improper use may affect the health of an infant.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/11\/a2-Gentle-Gold-Infant-formula-Stage-1-product-information-032024.pdf\">Click link to view Infant Formula Sample Information<\/a><\/div>\r\n<div><\/div>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/11\/Stage-1-a2-gentle-gold.png","cat_name":"Infant Formula","slug":"infant-formula","sku_code":null},{"ID":"4034","post_title":"a2 GENTLE GOLD\u2122  PREMIUM TODDLER MILK DRINK STAGE 3","post_content":"Click to view\u00a0a2 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/11\/Stage-3-a2-gentle-gold.png\">Gentle Gold\u2122 Premium Toddler Milk Stage 3 product information<\/a>\r\n<div><\/div>\r\n<div>\r\n<div><\/div>\r\n<div><\/div>\r\n<\/div>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/11\/Stage-3-a2-gentle-gold.png","cat_name":"Infant Formula","slug":"infant-formula","sku_code":null}],"iron-deficiency":[{"ID":"43715","post_title":"FERRO TAB","post_content":"<!--more-->Each tablet contains Ferrous Fumerate 200mg (equivalent to 67.5mg elemental iron) and does not include any other vitamins or minerals that can affect absorption<u>\r\n<\/u>\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 3 Ferro-Tab tablets down to 2 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-43-53-pm\/\"><img class=\"aligncenter size-full wp-image-43729\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.43.53-pm.png\" alt=\"\" width=\"504\" height=\"665\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-TAB-ANGLED.jpg","cat_name":"Iron Deficiency","slug":"iron-deficiency","sku_code":null},{"ID":"43716","post_title":"FERRO F TAB","post_content":"Each tablet contains Ferrous Fumerate 310mg (equivalent to elemental iron 100mg) + Folic Acid 350\u00b5g\r\n\r\nFlexible dosage helps to:\r\n1. Increase tolerability by:\r\n- Not consuming excess iron above what is required\r\n- Allowing multiple tablets to be taken, spread out over the course of the day\r\n2. Increase patient compliance by allowing the dosage to be adjusted\r\ne.g 2 Ferro-F-Tab tablets down to 1 tablets if side effects do occur, as opposed to completely stopping the therapy<u>\r\n<\/u>\r\n\r\n<b>PBS listed<\/b><u><\/u>\r\n\r\nPBS Information: Restricted benefit. For treatment of a patient identifying as Aboriginal or Torres Strait Islander. For RPBS information refer to PBS Schedule\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/screen-shot-2021-09-28-at-4-53-12-pm\/\"><img class=\"aligncenter size-full wp-image-43730\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-28-at-4.53.12-pm.png\" alt=\"\" width=\"536\" height=\"767\" \/><\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2018\/09\/FERRO-F-TAB-ANGLED.jpg","cat_name":"Iron Deficiency","slug":"iron-deficiency","sku_code":null}],"womens-health":[{"ID":"60856","post_title":"SANDRENA\u00ae","post_content":"Orion Pharma are pleased announce <strong>SANDRENA estradiol hemihydrate gel 0.1% 0.5g dose is PBS listed from 1<sup>st<\/sup> November 2024<\/strong>. The SANDRENA 1.0g dose remains PBS listed. The new 0.5g sachet allows for more accurate dose modification across the three TGA registered doses of 0.5mg, 1mg and 1.5mg SANDRENA estradiol 0.1% gel<sup>1<\/sup>.\r\n\r\n<img class=\"alignnone size-full wp-image-64780\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Picture1.png\" alt=\"\" width=\"236\" height=\"184\" \/>\r\n\r\nSandrena\u00ae estradiol (0.1% w\/w) gel is indicated for the short term of climacteric symptoms after natural or surgical menopause. Sandrena\u00ae is a high concentration, low volume gel, available in convenient individually dosed sachets\u00b9.\r\n\r\n<strong>Sandrena\u00ae (estradiol 0.1% w\/w) transdermal gel provides<\/strong>\r\n<ul>\r\n \t<li>Convenient, body-identical treatment for the symptoms of menopause.<\/li>\r\n \t<li>The flexibility to combine with the preferred form of progestogen in non-hysterectomised women\u00b9.<\/li>\r\n<\/ul>\r\nIrrespective of the dose, recommended application area is 1-2 times the size of the hand (200-400cm\u00b2) to the lower trunk or thigh. The gel should be allowed to dry for a few minutes before getting dressed\u00b2. Avoid washing the application site within an hour of applying the gel\u00b9,2.\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Sandrena-patient-application-2024.pdf\"><strong>CLICK HERE <\/strong><\/a>to access patient application information.\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Sandrena-A4-Clinical-Education-2025.pdf\"><strong>CLICK HERE<\/strong><\/a> to access healthcare professional information.\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Orion-Pharma_Prescribing-MHT-in-General-Practice.pdf\"><strong>CLICK HERE<\/strong><\/a> to access prescribing MHT in General Practice.\r\n\r\n<img class=\"alignnone size-full wp-image-64781\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Picture1-1.png\" alt=\"\" width=\"918\" height=\"109\" \/>\r\n\r\nPlease review product information before prescribing at\u00a0 <a href=\"https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&amp;t=pi&amp;q=sandrena\">Sandrena Product Information<\/a>\r\n\r\nReferences: 1. Sandrena\u00ae Product Information, 6<sup>th<\/sup> December 2023. 2. Hirvonen E, Crona N, Wahlstr\u00f6m T, B\u00e4ckstr\u00f6m A-C. Climacteric 2000; 3: 262\u2013270. Date of preparation January 2025 SA_AU_2025_01\r\n\r\nTo report an adverse event, or for medical information, email <a href=\"mailto:Medical.ANZ@pharmalex.com\">Medical.ANZ@pharmalex.com<\/a> or phone 1800 861 913.\r\n\r\nOrion Pharma\r\n\r\nLevel 24, Tower 3, 300 Barangaroo Avenue, Sydney NSW 2000\r\n\r\n+61 8067 8704\r\n\r\nEMAIL: <a href=\"mailto:contactusaustralia@orionpharma.com\">contactusaustralia@orionpharma.com<\/a>\r\nWEB: <a href=\"http:\/\/www.orionpharma.com.au\">www.orionpharma.com.au<\/a>\r\n\r\n&nbsp;","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/06\/Carton-Sandrena-.5g-and-1g-2024.jpg","cat_name":"Womens health","slug":"womens-health","sku_code":null},{"ID":"31227","post_title":"UTROGESTAN\u00ae","post_content":"<p class=\"p1\">Luteal Phase Support<sup>1<\/sup><\/p>\r\n<p class=\"p1\">Utrogestan is indicated for use in luteal phase support during Assisted Reproductive Treatment (ART) cycles and is reimbursed for the first two weeks following embryo transfer<sup>2<\/sup>.<\/p>\r\n<p class=\"p1\">Utrogestan is available as 200mg soft vaginal capsules in packs of 42 capsules (two weeks supply).<\/p>\r\n<p class=\"p1\">Dosage is three times daily, administered vaginally, from the day of embryo transfer until at least the 7th week of pregnancy and no later than the 12th week of pregnancy.<\/p>\r\n<p class=\"p1\">Utrogestan (micronised progesterone) is TGA-approved for prevention of preterm birth, in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix \u226425 mm) and\/or a history of spontaneous preterm birth.<sup>1<\/sup> Compared to placebo, vaginal progesterone significantly reduces the risk of preterm birth and improves perinatal outcomes in women with singleton pregnancy and a short cervix, with proven maternal and neonatal tolerability.<sup>1, 3-5<\/sup> Utrogestan vaginal capsules are administered once-daily, are easy to insert and readily absorbed.<sup>1<\/sup><\/p>\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li class=\"p1\">Utrogestan<sup>\u00ae<\/sup> (micronised progesterone) Product Information, updated 13 November 2019.<\/li>\r\n \t<li>Pharmaceutical Benefits Scheme\u00a0Available at <a href=\"https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines\">https:\/\/www.pbs.gov.au\/pbs\/search?term=utrogestan&amp;analyse=false&amp;search-type=medicines<\/a><\/li>\r\n \t<li class=\"p1\">Romero R et al. Am J Obstet Gynaecol 2018;218(2):161-80.<\/li>\r\n \t<li class=\"p1\">Norman JE et al. Lancet 2016;387:2106-16.<\/li>\r\n \t<li class=\"p1\">Fonseca EB et al. N Engl J Med 2007;357:462-9.<\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Utrogestan<sup>\u00ae<\/sup> is a registered trademark of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\n<p class=\"p1\">UTR0514<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Utrogestan-Packaging-Images_Utrogestan-Pack_Caps-1.jpg","cat_name":"Womens health","slug":"womens-health","sku_code":null},{"ID":"58350","post_title":"FEMME-TAB (30\/150)","post_content":"Available on the general schedule as an Unrestricted Benefit. Refer to PBS schedule for full information. Before prescribing, please review the full product information at <a href=\"http:\/\/www.aftpharm.co.au\/femmetab20100\">www.aftpharm.co.au\/femmetab20100<\/a> or <a href=\"http:\/\/www.afpharm.com\/femmetab30150\">www.afpharm.com\/femmetab30150<\/a> or on request from AFT Pharmaceuticals.\r\n\r\nFemme-Tab ED 30\/150 is a Prescription Only S4 medicine for use as oral contraception.\r\n\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\"><img class=\"size-full wp-image-45353 alignleft\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot-scaled-e1705966009893.jpg\" alt=\"\" width=\"250\" height=\"176\" \/><\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>FEMME-TAB ED 30\/150<\/strong>\r\n\r\nA high dose combination of Ethinyloestradiol 30 micrograms and Levonorgestrel 150 micrograms available on the PBS.\r\n\r\n28 x Film-coated Tablets\r\n\r\nAUST R 170389\r\n\r\n&nbsp;\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-PI.pdf\">Femme-tab 30.150 PI<\/a>\r\n\r\nClick here to view 30\/150 <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-tab-ED-30.150-CMI.pdf\">Customer leaflet<\/a>\r\n\r\nClick to view Femme-Tab <a href=\"https:\/\/mysamples.com.au\/femme-tab-swatch-sets_h\/\">Swatch Sets<\/a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<strong>PBS Information<\/strong>\r\n\r\nThese products are listed on the PBS as medicine for Oral Contraception.\r\n\r\n&nbsp;\r\n\r\n<strong>Product Mandatory statement<\/strong>\r\n\r\nS4 Prescription only medicine.\r\n\r\n&nbsp;\r\n\r\n<strong>Dosage<\/strong>\r\n\r\nOne tablet is to be taken daily. The tablets must be taken in the order directed on the package every day at about the same time. Daily tablet taking should be continuous for 28 consecutive days, starting with a tablet corresponding to that day of the week from the red section of the Femme-Tab pack. Each subsequent pack is started the day after the last tablet of the previous pack. Refer to insert for further information.\r\n\r\n&nbsp;\r\n\r\n<strong>Warnings<\/strong>\r\n\r\nProduct contains lactose.\r\n\r\nKeep out of reach of children.\r\n\r\nDo not use after the expiry date stated on the package.\r\n\r\nSee Minimum PI for further information.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/12\/Femme-Tab-ED-30-150-Packshot.jpg","cat_name":"Womens health","slug":"womens-health","sku_code":null},{"ID":"31226","post_title":"PROMETRIUM\u00ae","post_content":"<p class=\"p1\">Prometrium is approved for adjunctive use with estrogen in post-menopausal women with an intact uterus.<sup>1<\/sup> Prometrium is body-identical micronised progesterone providing endometrial protection for post-menopausal women with an intact uterus receiving estrogen therapy.<sup>1<\/sup> The therapy is also associated with a better risk profile for breast cancer compared to synthetic progestogens<sup>4<\/sup>, in addition to having a neutral effect on blood pressure and lipids.<sup>2<\/sup> Prometrium can be added to any estrogen therapy.<sup>1<\/sup> The usual dose is 100 mg (one capsule) taken at bedtime, from days 1 to 25 of each cycle. Alternatively, 200 mg\/day (two capsules) can be taken at bedtime on days 15 to 26 of each cycle.<sup>1<\/sup><\/p>\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li style=\"list-style-type: none;\">\r\n<ol>\r\n \t<li class=\"p1\">Prometrium<sup>\u00ae<\/sup> Approved Product Information, 20 June 2016.<\/li>\r\n \t<li class=\"p1\">Panay N. Post Reprod Health 2014;20:69-72.<\/li>\r\n \t<li class=\"p1\">The Writing Group for the PEPI Trial. JAMA 1996;275:370-375.<\/li>\r\n \t<li class=\"p1\">North American Menopause Society. Menopause 2012;19:257-271.<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Prometrium\u00ae is a registered trademark of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\nPROM0515","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Prometrium-100mg-pack-shot-1.png","cat_name":"Womens health","slug":"womens-health","sku_code":null},{"ID":"31225","post_title":"ESTROGEL\u00ae PRO","post_content":"<p class=\"p1\">Estrogel Pro is a medicine co-pack containing one pack of Estrogel (estradiol hemihydrate) plus one pack of Prometrium (micronised progesterone); the only medicine co-pack containing two body-identical menopausal hormone therapies for women with an intact uterus.<sup>1-4<\/sup> With the convenience of a single prescription, this combination of transdermal estradiol (Estrogel) and oral micronised progesterone (Prometrium) is supported by 35+ years of extensive clinical experience, and is recommended by local and international guidelines.<sup>2,3,5-8<\/sup><\/p>\r\n&nbsp;\r\n\r\n<a href=\"https:\/\/www.besins-healthcare.com.au\/healthcare-professionals\/\">CLICK HERE<\/a> FOR PI \/ CMI\r\n\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\">CLICK HERE<\/a> FOR BESINS WEBSITE\r\n\r\n&nbsp;\r\n<p class=\"p1\">[REFERENCES]<\/p>\r\n\r\n<ol>\r\n \t<li class=\"p1\">Estrogel Pro ARTG Public Summary Document, effective 23 October 2019. Available at\u00a0<a href=\"http:\/\/www.tga.gov.au\">www.tga.gov.au<\/a>; Accessed January 2020.<\/li>\r\n \t<li class=\"p1\">Estrogel<sup>\u00ae<\/sup> (estradiol hemihydrate) Product Information, updated 08 May 2019.<\/li>\r\n \t<li class=\"p1\">Prometrium<sup>\u00ae<\/sup> (micronised progesterone) Product Information, updated 20 June 2016.<\/li>\r\n \t<li class=\"p1\">Panay N. Post Reprod Health 2014;20:69\u201372.<\/li>\r\n \t<li class=\"p1\">Besins Data on File.<\/li>\r\n \t<li class=\"p1\">Cobin RH et al. Endocr Pract 2017;23(7):869\u2013880.<\/li>\r\n \t<li class=\"p1\">The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24(7):728-753.<\/li>\r\n \t<li class=\"p1\">The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Menopausal Hormone Therapy Advice; C-Gyn 16. Available at: <a href=\"https:\/\/www.ranzcog.edu.au\/\">https:\/\/www.ranzcog.edu.au\/<\/a> Accessed January 2020.<\/li>\r\n<\/ol>\r\n&nbsp;\r\n\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n<p class=\"p1\">Estrogel<sup>\u00ae<\/sup>\u00a0and Prometrium<sup>\u00ae<\/sup> are registered trademarks of Besins Healthcare.<\/p>\r\n<p class=\"p1\">Besins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473. <a href=\"http:\/\/www.besins-healthcare.com.au\">www.besins-healthcare.com.au<\/a><\/p>\r\n<p class=\"p1\">EPRO0015<\/p>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2020\/04\/Estrogel-Pro-pack-shot.jpg","cat_name":"Womens health","slug":"womens-health","sku_code":null},{"ID":"47809","post_title":"SLINDA\u00ae","post_content":"Slinda<sup>\u00ae<\/sup> is a progestogen-only contraceptive pill with similar efficacy to combined oral contraceptives, and a 24-hour missed pill window.<sup>1-4<\/sup> In the pivotal clinical trial programme, Slinda<sup>\u00ae<\/sup> resulted in 99% contraceptive efficacy (Pearl Index 0.73) in a broad patient population that included women with multiple cardiovascular risk factors, including smoking, obesity, and a family history of venous thromboembolism.<sup>1-4<\/sup>\r\n\r\nProgestogen-only contraceptives such as Slinda<sup>\u00ae<\/sup> may be more suitable than combined oral contraceptives for a broad range of women, particularly for those who want to avoid estrogen-related risks and side effects.<sup>4,5<\/sup>\r\n\r\nImportantly, Slinda<sup>\u00ae<\/sup> can be safely used in breastfeeding mothers.<sup>1,5<\/sup> Plus, Slinda<sup>\u00ae<\/sup> is simple to use, easy to start and follows a 24 + 4 dosing regimen.<sup>1<\/sup>\r\n<p class=\"p1\">Please review Product Information before prescribing.<\/p>\r\n<p class=\"p1\">The Product Information can be accessed <a href=\"https:\/\/besins-healthcare.com.au\/healthcare-professionals\/product-information\/\">here<\/a>\u00a0or telephone 1800 BESINS (237 467).<\/p>\r\n<a href=\"http:\/\/www.besins-healthcare.com.au\/\"><strong>CLICK HERE<\/strong><\/a> FOR BESINS HEALTHCARE WEBSITE\r\n\r\n<a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-e1630471245894.png\"><img class=\"aligncenter size-medium wp-image-43130\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/09\/Screen-Shot-2021-09-01-at-4.39.35-pm-300x68.png\" alt=\"\" width=\"300\" height=\"68\" \/><\/a>\r\n<p class=\"p1\">Minimum Product Information Slinda (drospirenone 4 mg) Indication: Contraception Contraindications: active venous thromboembolic disorder; presence or history of severe hepatic disease with abnormal liver function values; severe renal insufficiency or acute renal failure; known or suspected sex-steroid sensitive malignancies; undiagnosed vaginal bleeding; hypersensitivity to active substance or any excipients. Clinically significant precautions: a complete medical history should be taken and pregnancy excluded, patients should be counselled that contraceptives do not protect against HIV or STIs; efficacy can be reduced with missed pills and gastrointestinal disturbances; hyperkalaemia (monitor serum potassium levels in patients presenting with renal insufficiency and pre-treatment potassium in upper reference range); risk of stroke and VTE may be slightly increased with progestogen-only preparations; discontinue Slinda with pregnancy, symptoms of thrombosis, jaundice, sustained hypertension; consider discontinuation with prolonged immobilisation; decreased estradiol levels may affect bone metabolism; breast cancer risk may be similar to that associated with COC use; rare cases of liver tumours with hormonal contraceptive use; new amenorrhea or abdominal pain may indicate ectopic pregnancy; monitor for altered insulin and glucose tolerance in diabetic patients, mood and depressive symptoms; changes in menstrual bleeding and chloasma may occur. Clinically significant interactions: enzyme-inducing drugs can lead to contraceptive failure and\/or breakthrough bleeding, patients on long-term treatment are advised not to use Slinda; certain medications increase clearance of contraceptive hormones (e.g. barbiturates, bosentan, carbamazepine, phenytoin, rifampicin); HIV\/HCV medications can alter progestin concentrations; CYP3A4 enzyme inhibitors such as azole antifungals, verapamil, macrolides, diltiazem and grapefruit juice can increase plasma progestogen concentrations; Slinda may affect cytochrome P450 metabolism of other active substances (e.g. cyclosporine, lamotrigine); monitor for hyperkalaemia with use of potassium-sparing medicines. Very common and common adverse effects: acne, changes in menstrual bleeding (metrorrhagia, vaginal haemorrhage, dysmenorrhea, menstruation irregular), headache, breast pain, libido and mood changes, nausea, abdominal pain, weight increased (see full PI). Dosage and method of use: tablets must be taken orally the same time each day without a break in daily tablet intake; 7 days of uninterrupted tablet intake is required to attain adequate contraception; contraceptive protection is not reduced if a patient is less than 24 hours late in tablet intake; management of missed tablets (more than 24 hours late) is dependent on stage of menstrual cycle (see full PI); consider additional contraceptive measures with gastrointestinal disturbances.<\/p>\r\n<strong>References: <\/strong>\r\n<ol>\r\n \t<li>Slinda<sup>\u00ae<\/sup> (drospirenone) Product Information, accessed July 2021.<\/li>\r\n \t<li>Archer D <em>et al. Contraception<\/em> 2015;92(5):439-44.<\/li>\r\n \t<li>Palacios S <em>et al. Acta Obstet Gynecol Scand<\/em> 2019;98(12):1549-57.<\/li>\r\n \t<li>Palacios S <em>et al. Eur J Contracept Reprod Health Care<\/em> 2020;25(3):221-27.<\/li>\r\n \t<li>Family Planning New South Wales, Family Planning Victoria and True Relationships and Reproductive Health. Contraception: An Australian Clinical Practice Handbook, 4<sup>th<\/sup> edition. Ashfield NSW, 2016.<\/li>\r\n<\/ol>\r\nTo request a copy of the Product Information or to report adverse events, please call Besins Medical Information on 1800 BESINS (1800 237 467).\r\n\r\nSlinda<sup>\u00ae<\/sup> is a registered trademark of Chemo Research S.L.\r\n\r\nBesins Healthcare Australia Pty Ltd. ABN 68 164 882 062. Suite 3, Level 2, Tower 1, 495 Victoria Ave, Chatswood, NSW 2067. Office phone (02) 9904 7473.\u00a0<a href=\"http:\/\/www.besins-healthcare.com.au\/\">www.besins-healthcare.com.au<\/a>\r\n\r\nSLI-1001","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/07\/Slinda-box.jpeg","cat_name":"Womens health","slug":"womens-health","sku_code":null}],"allergies":[{"ID":"60224","post_title":"Novalac Reflux Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Reflux<\/strong> specialty infant formula is specifically formulated to help resolve reflux symptoms in infants, leading to a significant reduction in regurgitations, decreased time for bottle feeding, and increased volume of feeds.<sup>1<\/sup>\r\n\r\nKey benefits of Novalac Reflux:\r\n<ul>\r\n \t<li>81% of reflux case in infants resolved within 6 days<sup>1<\/sup><\/li>\r\n \t<li>Novalac Reflux has been shown to:\r\n<ul>\r\n \t<li>significantly reduce frequency and intensity of regurgitations and exposure of the oesophageal mucosa to acid.<sup>2<\/sup><\/li>\r\n \t<li>significantly increase feeding volume, gastric emptying and weight gain.<sup>3<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Thickens in the stomach, not the bottle, so it is easy for baby to drink and helps the feed stay down.<sup>1<\/sup><\/li>\r\n \t<li>Casein-dominant formula which helps prevent regurgitation and, in conjunction with specially treated cornstarch, encourages gastric emptying.<sup>1,3<\/sup><\/li>\r\n \t<li>Contains cornstarch with a high level of amylopectin for ease of digestion.<sup>2,4,5<\/sup><\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Product-Information-and-Evidence.pdf\">Novalac Reflux Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Reflux-Nutritional-Information.pdf\">Novalac Reflux Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008;14(2):248\u201354.<\/li>\r\n \t<li>Xinias I, et al. Dig Liver Dis. 2005;37(1):23\u201327.<\/li>\r\n \t<li>Chao HC, et al. Dis Esophagus. 2007;20(2):155-60.<\/li>\r\n \t<li>Ketthaisong, et al. J Food Sci Technol, 2015; 52, 6529\u20136537.<\/li>\r\n \t<li>Lin A, et al. Molecules, 2017;22, 1526<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Reflux_PackShot.jpg","cat_name":"Allergies","slug":"allergies","sku_code":null},{"ID":"60218","post_title":"Novalac Constipation Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Constipation<\/strong> is specifically formulated to provide a balanced blend of nutrients to help soften stools, increase stool frequency, and relieve pain and discomfort.<sup>1-4<\/sup>\r\n\r\nKey benefits of Novalac Constipation:\r\n<ul>\r\n \t<li>91.6% of cases of infant constipation resolved within 7 days<sup>1<\/sup><\/li>\r\n \t<li>Helps manage constipation without the use of laxatives while giving babies essential nutrients.<sup>2-4<\/sup><\/li>\r\n \t<li>Novalac Constipation has been shown to significantly:\r\n<ul>\r\n \t<li>increase the water content of stools<sup>2<\/sup><\/li>\r\n \t<li>improve stool consistency and frequency<sup>1-4<\/sup><\/li>\r\n \t<li>reduce pain and discomfort with defecation<sup>1-3<\/sup><\/li>\r\n \t<li>reduce the need for manual assistance with defecation<sup>1,2<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Shortens intestinal transit time by increasing the osmotic load through a specially formulated combination of:\r\n<ul>\r\n \t<li>increased lactose (100% of carbohydrates) - produces an osmotic effect and may create a prebiotic effect when metabolised in the colon to help stimulate bowel movements<sup>1-3<\/sup><\/li>\r\n \t<li>increased magnesium to help increase water content<sup>1,4<\/sup><\/li>\r\n \t<li>an optimal calcium to phosphorus ratio of 2:1 which helps soften stools<sup>4-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Information-and-Evidence-NOV-08668-E0726.pdf\">Novalac Constipation Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Constipation-Nutritional-Information.pdf\">Novalac Constipation Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li style=\"list-style-type: none;\">\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol 2008;14(2):248\u2013254.<\/li>\r\n \t<li>Infante DD, et al. Nut Journal. 2011;10:55.<\/li>\r\n \t<li>Le Luyer B, et al. RIP 2002; Tome XXXI;316:5\u20138. 33.<\/li>\r\n \t<li>Benninga MA, et al. Pediatr Gastroenterol Hepatol Nutr 2019;22(3):270281.<\/li>\r\n \t<li>Kesavelu D, et al. Clin Ep &amp; Glob Health 6. 2018;5\u20139.<\/li>\r\n \t<li>Khinchi M, et al. J Pediatr Gastroenterol &amp; Nutr. 1999;28(5):591.<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Constip_PackShot.jpg","cat_name":"Allergies","slug":"allergies","sku_code":null},{"ID":"60228","post_title":"Novalac Colic Premium Specialty Infant Formula 800g","post_content":"<strong>NOVALAC Colic<\/strong> has been scientifically formulated for infants with colic and associated symptoms such as gas and bloating.\r\n\r\nKey benefits of Novalac Colic:\r\n<ul>\r\n \t<li>87.6% of cases of colic in infants were shown to be resolved within 8 days<sup>1<\/sup><\/li>\r\n \t<li>Has been shown to significantly reduce gas, intestinal bloating and crying<sup>1,2<\/sup><\/li>\r\n \t<li>Contains easily digestible maltodextrin (70% of total carbohydrates) and a reduced proportion of lactose (30% of total carbohydrates) to reduce the risk of excessive gas which may be caused by the malabsorption of\u00a0lactose in the colon.<sup>2,3<\/sup><\/li>\r\n \t<li>Contains a Casein: Whey ratio of 40:60 to ease digestive discomfort to help infants to settle.<sup>4,5<\/sup><\/li>\r\n \t<li>Manages colic whilst feeding and nourishing baby with essential vitamins and minerals.<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Information-and-Evidence-NOV-08669-E0726.pdf\">Novalac Colic Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Colic-Nutritional-Information.pdf\">Novalac Colic Nutritional Information<\/a><\/li>\r\n<\/ul>\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\nNot suitable for general use and should be used under medical supervision.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Infante Pina D, et al. World J Gastroenterol. 2008; 14(2):248\u201354.<\/li>\r\n \t<li>Infante DD, et al. World J Gastroenterol. 2011;17(16):2104\u20138.<\/li>\r\n \t<li>Hofman DL, et al. Crit Rev Food Sci Nutr. 2016; 56(12):2091\u2013100.<\/li>\r\n \t<li>Martin CR, et al. Nutrients. 2016; 8(5):279.<\/li>\r\n \t<li>Rafiee Tari N, et al. J Dairy Sci 2018;101(4): 2851\u201361.<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/240116_Novalac_Colic_PackShot.jpg","cat_name":"Allergies","slug":"allergies","sku_code":null},{"ID":"42837","post_title":"Novalac Allergy Premium Infant Formula Powder 800g","post_content":"<strong>NOVALAC Allergy<\/strong> has been scientifically formulated from protein sourced from rice, for babies unable to tolerate cow\u2019s milk formula or with a confirmed cow\u2019s milk protein allergy (CMPA). Novalac Allergy is also suitable for lactose intolerant babies.\r\n\r\nKey benefits of Novalac Allergy:\r\n<ul>\r\n \t<li><strong>The Australasian Society of Clinical Immunology and Allergy (ASCIA) recommends rice protein-based infant formula as a first choice for infants with CMPA when breastfeeding is not possible<sup>1*<\/sup><\/strong>\r\n<ul>\r\n \t<li><strong>Novalac Allergy is the\u00a0<u>only<\/u> rice protein based infant formula in the ASCIA guidelines that has product specific hypo-allergenicity and growth studies.<sup>1<\/sup><\/strong><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Hypoallergenic - Tolerated by &gt;90% of infants with confirmed CMPA<sup>2-4<\/sup>\r\n<ul>\r\n \t<li>Reduces allergy symptoms associated with CMPA including regurgitation, eczema, diarrhoea and constipation<sup>2-4<\/sup><\/li>\r\n \t<li>Helps babies return to normal weight &amp; growth patterns<sup>2-6<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Pleasant taste, unlike some extensively hydrolysed or amino-acid-based formulas<sup>2,3,7<\/sup><\/li>\r\n \t<li>Suitable to lactose-intolerant babies<\/li>\r\n \t<li>Nutritionally complete and suitable for ongoing use from birth to 12 months.<sup>#<\/sup><\/li>\r\n \t<li>Contains Omega 3 (\u03b1-Linolenic acid) and 6 (Linoleic acid) from vegetable source<\/li>\r\n \t<li><strong>No prescription needed<\/strong> (Available only from pharmacy and online)<\/li>\r\n<\/ul>\r\nClick to view:\r\n<ul>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/Novalac-Allergy-Product-Information-and-Evidence.pdf\">Novalac Allergy Product Information and Evidence<\/a><\/li>\r\n \t<li><a href=\"https:\/\/www.allergy.org.au\/hp\/papers\/guide-for-milk-substitutes-cows-milk-allergy\"><u>Australasian Society of Clinical Immunology and Allergy (ASCIA) Guide for Milk Substitutes in Cow\u2019s Milk Allergy\u00a0<\/u><\/a><\/li>\r\n \t<li><a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2021\/08\/Novalac-Allergy-NIP-AF-07488-2.pdf\">Novalac Allergy Nutritional Information Panel\u00a0<\/a><\/li>\r\n<\/ul>\r\n*Unless allergic to rice.\r\n\r\n#Babies aged over 6 months should be offered solid food in addition to infant formula.\r\n\r\n<img class=\"alignnone size-full wp-image-60222\" src=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/04\/conditions.png\" alt=\"\" width=\"955\" height=\"495\" \/>\r\n\r\n<strong>IMPORTANT NOTICE<\/strong>: <strong>BREAST MILK IS BEST FOR BABIES:<\/strong> Professional advice should be followed before considering an infant formula. Good maternal nutrition is important for the maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing the decision not to breastfeed will be difficult. Before deciding to use infant formula, also consider the financial implications of needing to purchase formula until the baby is 12 months old. Infant formula should be prepared and used as directed otherwise it could pose a health risk.\r\n\r\n<strong>\u00a0<\/strong><strong>References:<\/strong>\r\n<ol>\r\n \t<li>Australasian Society of Clinical Immunology and Allergy (ASCIA), Guide for milk substitutes in cow\u2019s milk allergy, June 2023.<\/li>\r\n \t<li>Vandenplas Y et al. Eur J Paediatr. 2014; 173(9);1209-16<\/li>\r\n \t<li>Vandenplas Y et al. Arch Dis Child. 2014; 99:933-6<\/li>\r\n \t<li>Reche M et al. Patriatr Allergy Immunol. 2010; 21:577-85<\/li>\r\n \t<li>D\u2019Auria E et al. J Int Med Res. 2003; 31:215-22<\/li>\r\n \t<li>Agostoni C et al. Pediatr Allergy Immunol. 2007; 18:599-606<\/li>\r\n \t<li>Pedrosa M et al. J Investig Allergol Clin Immunol. 2006; 16:351-6<\/li>\r\n<\/ol>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-15-at-11.36.22-am.png","cat_name":"Allergies","slug":"allergies","sku_code":null}],"pain-relief":[{"ID":"3957","post_title":"MAXIGESIC","post_content":"Developed in New Zealand, Maxigesic\u00ae is a unique, patented combination of paracetamol 500mg and ibuprofen 150mg that provides fast, effective double action relief for a wide range of pain symptoms, and also reduces inflammation and fever.\r\n\r\nAt maximum dosage, Maxigesic\u00ae is clinically proven to provide better, faster pain relief than paracetamol or ibuprofen alone<sup>1<\/sup>:\r\n<ul>\r\n \t<li>78% more effective relief than paracetamol alone<sup>1<\/sup><\/li>\r\n \t<li>36% more effective relief than ibuprofen alone<sup>1<\/sup><\/li>\r\n \t<li>Faster meaningful pain relief than paracetamol or ibuprofen alone<sup>1<\/sup><\/li>\r\n<\/ul>\r\nMaxigesic\u00ae also provides significantly more effective pain relief than paracetamol or ibuprofen alone within the first dosing period (6 hours)<sup>1<\/sup>, and is the only combination analgesic that provides the maximum recommended daily OTC dose of paracetamol 4000mg and ibuprofen 1200mg, if required (2 tablets, four times per day).\r\n\r\nMaxigesic\u00ae is also a well-tolerated combination for patients, with no more adverse events than paracetamol or ibuprofen alone<sup>2<\/sup>.\r\n\r\nMaxigesic\u00ae is indicated for the temporary relief of pain and reduction of fever and the discomfort associated with fever. It is suitable for the temporary relief of pain associated with headache, migraine headache, tension headache, toothache, dental procedures, backache, arthritis, rheumatic pain, period pain, muscular pain, tennis elbow, sinus pain, sore throat, and aches and pains associated with colds and flu.\r\n\r\nMaxigesic\u00ae is an unfunded medicine - available from pharmacies (10, 20, 50 and 100 tablets) and supermarkets (10 and 20 tablets).\r\n\r\n<em>Contraindications:<\/em> Hypersensitivity to any ingredient. Existing peptic ulceration or other stomach disorders, asthma, impaired kidney function or heart failure. Urticaria or rhinitis associated with aspirin or other NSAID\u2019s. Pregnancy except on doctor\u2019s advice. Do not use in the last trimester of pregnancy. Do not use in children under 12 years.\r\n\r\n<em>Precautions: <\/em>Do not combine with any other paracetamol or ibuprofen containing medications. Asthma, stomach ulcer, kidney disease, liver disease, heart failure, high blood pressure.\r\n\r\n<em>Adverse Effects:<\/em> Nausea, dyspepsia, rash, constipation, dizziness, oedema, tinnitis, headache, gastrointestinal bleeding (rare at OTC dose). Hepatic dysfunction and papillary necrosis may occur.\r\n\r\n<em>Interactions:<\/em> Anticoagulant medication, diuretics, lithium, methotrexate, or other medicines for pain relief.\r\n\r\n<em>Directions for use: <\/em>\r\n\r\nAdults and children over 12 years: Take 1 or 2 tablets every 4-6 hours, as required, up to a maximum of 8 tablets in 24 hours. Not recommended for children under 12 years of age.\r\n\r\n&nbsp;\r\n\r\nClick here to access the <a href=\"https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/m\/maxigesictab.pdf\">Maxigesic datasheet<\/a>\r\n\r\nClick here to visit the <a href=\"https:\/\/maxigesic.co.nz\/\">Maxigesic\u00ae website<\/a>\r\n\r\nClick here to view the Maxigesic\u00ae detail aid\r\n\r\nClick here to view Maxigesic\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/748yPa7vRTs\">Brand<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/txSmp6USzdc\">Back Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/GgVHJH5zb-I\">Headache<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/qoguNnEWhg8\">Joint Pain<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/W_coLBBWHU0\">Period Pain #1<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/aB4DBvMiDF0\">Period Pain #2<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Daniels et al (2018). Result achieved in a trial of post-operative pain relief after removal of at least 2 wisdom teeth using MAXIGESIC\u00ae (Paracetamol 975mg\/Ibuprofen 292.5mg) compared with Paracetamol 975mg or Ibuprofen 292.5mg alone 4 times a day (Paracetamol 3900mg or Ibuprofen 1170mg per day). Study results assessed on the intent-to-treat (ITT) population with adjustment for the use of rescue medication. MAXIGESIC\u00ae 975\/292.5mg US combination is bioequivalent to MAXIGESIC\u00ae 1000\/300mg NZ combination at full dose (Aitken et al, 2018). Research sponsored by AFT Pharmaceuticals. 2. Aitken P, Stanescu I, Playne R, Zhang J, Frampton C and Atkinson HC (2019). \u201cAn Integrated Safety Analysis of Combined Acetaminophen and ibuprofen (MAXIGESIC\u00ae\/Combogesic\u00ae) in Adults\u201d, Journal of Pain Research 2019:12 621-634.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\nAFT Pharmaceuticals Ltd, Auckland\r\n\r\n<strong><em>Freephone:<\/em><\/strong> \u00a0\u00a0\u00a0 0800 423 823\r\n\r\n<strong><em>Freefax:<\/em><\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0800 423 874\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-9.55.50-PM.png","cat_name":"Pain Relief","slug":"pain-relief","sku_code":null}],"gastro-health-digestion":[{"ID":"63388","post_title":"GLUTEGUARD \u2013 GLUTEN DEGRADING ENZYME","post_content":"<strong>For Patients on a Gluten Free Diet<\/strong>\r\n\r\nAdherence to a strict gluten free diet is essential and the only treatment for those suffering from coeliac disease and other gluten related sensitivities.\r\n\r\n<strong>Where Strict Avoidance of Gluten Can be Very Challenging<\/strong>\r\n\r\nDespite trying to maintain a gluten free diet, unintended gluten ingestion can still occur.\r\n<ul>\r\n \t<li><strong>91% of coeliac patients<\/strong> report regular accidental gluten consumption.<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a><\/li>\r\n \t<li><strong>80 % of non-coeliac gluten sensitivity patients <\/strong>report accidental gluten consumption at least once in 2 months.<a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a><\/li>\r\n \t<li><!--StartFragment --><span class=\"cf0\"><strong>56% of coeliac patient<\/strong>s were shown to have ongoing intestinal damage despite adhering to a gluten free diet. <\/span><a href=\"#_ftn3\" name=\"_ftnref3\">[3]<\/a><\/li>\r\n<\/ul>\r\n<strong>And Result in Unwanted Symptoms<\/strong>\r\n\r\n<!--StartFragment --><span class=\"cf0\">Accidental gluten ingestion<\/span><!--EndFragment --> and the resulting symptoms can be very disruptive.\r\n<ul>\r\n \t<li><!--StartFragment --><span class=\"cf0\">As little as <strong>10mg of gluten<\/strong> can trigger symptoms in the most sensitive individuals<\/span><!--EndFragment -->.<a href=\"#_ftn4\" name=\"_ftnref4\">[4]<\/a><\/li>\r\n \t<li>Regular consumption of <strong>50mg of gluten<\/strong> is sufficient to cause villous atrophy in most coeliac patients.<a href=\"#_ftn4\" name=\"_ftnref4\">[4]<\/a><\/li>\r\n \t<li>Causing<strong> increased anxiety, hypervigilance and self-isolation<\/strong> leading to reduced emotional quality of life.<a href=\"#_ftn5\" name=\"_ftnref5\">[5]<\/a><a href=\"#_ftn6\" name=\"_ftnref6\">[6]<\/a><a href=\"#_ftn7\" name=\"_ftnref7\">[7]<\/a><a href=\"#_ftn8\" name=\"_ftnref8\">[8]<\/a><\/li>\r\n<\/ul>\r\n<strong>This is Where GluteGuard Helps \u2013 For Use as a Protective Measure When Accidental Gluten Ingestion is a Risk<\/strong>\r\n\r\nUse as required, one tablet before a meal when it cannot be certain it is free from gluten contamination. Such as when eating meals prepared by others: when travelling; at restaurants and cafes; takeaways; or catered events.\r\n\r\n<!--StartFragment -->\r\n<p class=\"pf0\"><span class=\"cf0\">GluteGuard\u2019s Caricain enzyme targets and breaks down the toxic gluten peptides known to cause symptoms, inflammation, and other complications, before they interact with the intestinal lining.<\/span><\/p>\r\n<strong>A Backup Tool to Partner with the Gluten Free Diet<\/strong>\r\n\r\n<!--StartFragment -->\r\n<p class=\"pf0\"><span class=\"cf0\">GluteGuard is to be used in conjunction with a gluten free diet, not to replace it. By providing an extra layer of protection, GluteGuard helps to reduce the occurrence of symptoms caused by accidental gluten ingestion in medically diagnosed gluten sensitivities. <\/span><\/p>\r\nLearn how GluteGuard works:\r\n\r\nhttps:\/\/youtu.be\/LxaWLLmRy2U?feature=shared\r\n\r\n&nbsp;\r\n\r\n<strong>Medically Demonstrated in coeliac Patients <\/strong>\r\n\r\nThe efficacy and safety of GluteGuard were demonstrated in randomised, double-blind, Placebo-controlled trials. \u00a0GluteGuard demonstrated significant protection from gluten induced symptoms in participants with coeliac disease and dermatitis herpetiformis.\r\n\r\nLearn more about the GluteGuard Clinical Trials <a href=\"https:\/\/professionals.glutagen.com\/clinical-trials\/\">here<\/a>\r\n\r\nDownload the GluteGuard Clinical Trial Summary <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/10\/Clinical-Summary-Both-pages-v.1.pdf\">here<\/a>\r\n\r\nDownload Pharmacy Information <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/10\/GluteGuard-Pharmacy-A4-Handout.pdf\">here<\/a>\r\n\r\nDownload the HCP Information <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/10\/2024-GluteGuard-A4-HCP-Flyer.pdf\">here<\/a>\r\n\r\n<strong>GluteGuard\u2019s Unique Active Ingredient <\/strong>\r\n\r\nGluteGuard contains the unique enzyme Caricain, naturally-derived from the skin of unripe papaya fruit. Caricain is able to hydrolyse key peptide bonds within the gluten protein, that would otherwise trigger gluten related symptoms, inflammation and the associated autoimmune response.\r\n\r\nClick <a href=\"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/10\/Caricain-Effects-Comparison-Full-Portrait@0.75x@0.75x.png\">here<\/a> to learn more about Caricain\u2019s unique mode of action\r\n\r\n<strong>When to recommend GluteGuard <\/strong>\r\n\r\nGluteGuard can be used as needed, before meals where there is a risk of gluten ingestion, such as when:\r\n<ul>\r\n \t<li>Eating out or takeaways<\/li>\r\n \t<li>Travelling<\/li>\r\n \t<li>Social occasions<\/li>\r\n \t<li>Catered events<\/li>\r\n \t<li>Uncertain ingredient labelling<\/li>\r\n \t<li>When gluten containing medications are required<\/li>\r\n<\/ul>\r\n<strong>Important Information <\/strong>\r\n<ul>\r\n \t<li>To be used in conjunction with a gluten free diet.<\/li>\r\n \t<li>Maximum daily dosage should not exceed 4 tablets unless otherwise recommended by a healthcare professional.<\/li>\r\n \t<li>Recommended for adults aged 18 years and older.<\/li>\r\n<\/ul>\r\n<strong>Warnings<\/strong>\r\n<ul>\r\n \t<li>Do not use if pregnant or breastfeeding.<\/li>\r\n \t<li>Do not use if allergic to papaya (paw paw) or natural latex rubber.<\/li>\r\n \t<li>Do not use if taking blood-thinning medication (warfarin)<\/li>\r\n \t<li>GluteGuard contains sulfites.<\/li>\r\n \t<li>Discontinue use if symptoms persist, worsen or episodes become more frequent. Always read the label and follow the directions for use.<\/li>\r\n<\/ul>\r\n\r\n<hr \/>\r\n\r\n<a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> <em>Silvester J, et al, \u2018Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet\u2019. (2016) 44 Alimentary Pharmacology and Therapeutics 612\u2013619.<\/em>\r\n\r\n<a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> <em>Vawser &amp; Associates, \u2018Research with people suffering gluten related disorders\u2019, commissioned by Glutagen, July 2020.<\/em>\r\n\r\n<a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> <em>Ciacci et al. 2002- Long-Term Follow-Up of coeliac Adults on Gluten-Free Diet: Prevalence and Correlates of Intestinal Damage.Digestion; 66(3):178-85.<\/em>\r\n\r\n<a href=\"#_ftnref4\" name=\"_ftn4\">[4]<\/a> Catassi C, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease; <em>Am J Clin Nutr<\/em>, 2007:85;160-166.\r\n\r\n<a href=\"#_ftnref5\" name=\"_ftn5\">[5]<\/a> Harnett et. al. (2020)- Quality of life in people with ongoing symptoms of coeliac disease despite adherence to a strict gluten\u2013free diet; Nature Research (2020) 10:1144\r\n\r\n<a href=\"#_ftnref6\" name=\"_ftn6\">[6]<\/a> B - Vis, &amp; Scheepers. (2017)- Social implications of celiac disease or non-celiac gluten sensitivity. International Journal of Celiac Disease, vol. 5(4), p.133-139.\r\n\r\n<a href=\"#_ftnref7\" name=\"_ftn7\">[7]<\/a> Lee et. al. (2012)- Living with coeliac disease: survey results from the USA; Journal of Human Nutrition &amp; Dietetics, vol. 25, pp. 233-238.\r\n\r\n<a href=\"#_ftnref8\" name=\"_ftn8\">[8]<\/a> Wolf et. al. (2018)- Hypervigilance to a gluten-free diet and decreased quality of life in teenagers and adults with celiac disease. Digestive Diseases and Sciences. doi: 10.1007\/s10620-018-4936-4.","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2024\/10\/API-188504-GluteGuard-10PK-936998199518.jpg","cat_name":"Gastro Health &amp; Digestion","slug":"gastro-health-digestion","sku_code":null}],"first-aid":[{"ID":"3692","post_title":"CRYSTADERM","post_content":"Crystaderm\u00ae (Hydrogen Peroxide cream 1% w\/w, 10g and 15g) is a first aid antiseptic cream for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, burns and school sores (impetigo).\r\n\r\nCrystaderm\u00ae is a broad-spectrum, preservative-free antiseptic cream that slowly releases hydrogen peroxide from lipid crystals for effective protection against skin infection with no known bacterial resistance<sup>1<\/sup> unlike topical antibiotics. Hydrogen peroxide is a potent agent against many types of bacteria, some fungi, and viruses, that acts by destroying essential components of the cells of these organisms.\r\n\r\nCrystaderm\u00ae dries fast and adheres to both moist and dry areas, and doesn\u2019t stain skin, hands and fabric. A small amount of Crystaderm\u00ae goes a long way so can be applied sparingly, and the smooth, pearly white cream vanishes quickly on application.\r\n\r\nCrystaderm\u00ae 10g cream is a fully funded general sales medicine - available from pharmacies and supermarkets. Crystaderm\u00ae 15g is an unfunded medicine.\r\n\r\n<em>Contraindications:<\/em> Known hypersensitivity to any ingredient.\r\n\r\n<em>Precautions: <\/em>Use under medical guidance in pregnancy and breastfeeding. Avoid contact with the eyes. Do not use in the presence of iodine, permanganate and any other strong oxidising agents.\r\n\r\n<em>Adverse Effects:<\/em> Mild sensation of burning may be experienced for a short time after application.\r\n\r\n<em>Directions for use: <\/em>After cleansing the area, apply cream 2-3 times daily on affected area. A dry film will appear on the skin after application, which can be washed off with water.\r\n\r\n&nbsp;\r\n\r\nClick here to visit the <a href=\"https:\/\/crystaderm.co.nz\/\">Crystaderm website<\/a>\r\n\r\nClick here to view the Crystaderm\u00ae detail aid\r\n\r\nClick here to view Crystaderm\u00ae videos:\r\n<ul>\r\n \t<li><a href=\"https:\/\/youtu.be\/oNg9uWKfm2k\">First Aid video<\/a><\/li>\r\n \t<li><a href=\"https:\/\/youtu.be\/tGINSugNu5I\">Acne video<\/a><\/li>\r\n<\/ul>\r\n<strong>\u00a0<\/strong>\r\n\r\n<strong>Reference:<\/strong> 1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy for Treating Chronic Wounds, 2009, 49:1541\u20131549.\r\n\r\n<strong>Contact Information<\/strong>\r\n\r\n<strong><em>Email:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 customer.service@aftpharm.com\r\n\r\n<strong><em>Website:<\/em><\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a href=\"http:\/\/www.aftpharm.com\">www.aftpharm.com<\/a>","guid":"https:\/\/mysamples.com.au\/wp-content\/uploads\/2023\/08\/Screenshot-2023-08-03-at-10.00.13-PM.png","cat_name":"First Aid","slug":"first-aid","sku_code":null}]}